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Abstract
One of the major concerns in the practice of allergy is related to the safety of procedures for the diagnosis and
treatment of allergic disease. Management (diagnosis and treatment) of hypersensitivity disorders involves often
intentional exposure to potentially allergenic substances (during skin testing), deliberate induction in the office of
allergic symptoms to offending compounds (provocation tests) or intentional application of potentially dangerous
substances (allergy vaccine) to sensitized patients. These situations may be associated with a significant risk of
unwanted, excessive or even dangerous reactions, which in many instances cannot be completely avoided.
However, adverse reactions can be minimized or even avoided if a physician is fully aware of potential risk and is
prepared to appropriately handle the situation.
Information on the risk of diagnostic and therapeutic procedures in allergic diseases has been accumulated in the
medical literature for decades; however, except for allergen specific immunotherapy, it has never been presented in
a systematic fashion. Up to now no single document addressed the risk of the most commonly used medical
procedures in the allergy office nor attempted to present general requirements necessary to assure the safety of
these procedures.
Following review of available literature a group of allergy experts within the World Allergy Organization (WAO),
representing various continents and areas of allergy expertise, presents this report on risk associated with diagnostic
and therapeutic procedures in allergology and proposes a consensus on safety requirements for performing
procedures in allergy offices. Optimal safety measures including appropriate location, type and required time of
supervision, availability of safety equipment, access to specialized emergency services, etc. for various procedures
have been recommended.
This document should be useful for allergists with already established practices and experience as well as to other
specialists taking care of patients with allergies.
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Introduction
Over the last several decades allergy practice has been
expanding worldwide in parallel with the increasing
number of patients suffering from allergic diseases. It
has been widely accepted that appropriate training and
certification are necessary for the physician to correctly
diagnose and manage allergic diseases. However, in some
countries the allergy specialty is still poorly developed or
does not exist. Allergy practice, therefore, varies from
country to country and according to local regulations or
traditions both trained allergists or physicians with other
specialties are performing allergy procedures such as
skin testing or immunotherapy. Furthermore, in several
regions of the world the increasing number of allergy
sufferers has not been matched by an appropriate supply
of trained specialists; as a result, physicians without
training in allergy including general practitioners and
pediatricians will be assisting allergic patients more and
more.
Doctors dealing with allergic diseases (certified aller-
gists or other specialists trained in allergy) are employ-
ing, in the office, various diagnostic and therapeutic
procedures which are associated with a significant risk
of unwanted reactions for a patient. The reactions, de-
pending on the procedure, may vary from local discom-
fort to severe anaphylaxis and death. Most unwanted
reactions can be either avoided or the risk/symptom in-
tensity may be minimized if the procedures are per-
formed in an appropriate manner. However, certain risk
of unwanted and or excessive reaction remains even if
all precautions are respected. During some diagnostic
procedures, called provocations (e.g. oral drug or food
challenges), the allergist deliberately aims at inducing
adverse symptoms which are mimicking those occurring
at natural exposure and sometimes may be associated
with a significant discomfort and even with some risk to
the patient. In such situations unpleasant or even poten-
tially dangerous symptoms are inherent to the procedure
and cannot be completely avoided. Thus, it is critical
that well established inclusion/exclusion criteria for the
challenge are considered and the protocols of provoca-
tions are strictly followed. Furthermore the patient
should be appropriately monitored by trained and expe-
rienced medical staff not only during the whole proced-
ure but also for an appropriate time after its completion.
Such precautions usually allow for a significant reduc-
tion of risk of unwanted or excessive symptoms.
The literature on the risk of allergic procedures exists,
but it has not been recently reviewed in a systematic
way. Furthermore, there is no available consensus on
safety requirements for performing specific diagnostic
procedures. Thus it is important to reach the consensus
on optimal safety measures (e.g. appropriate location,
type and required time of supervision, availability of
safety equipment, access to specialized emergency ser-
vices, etc.) for various procedures.
An international group of experts collaborating within
the World Allergy Organization (WAO) presents this
consensus report assessing risk and proposing safety re-
quirements for performing procedures in allergy offices.
This document refers to available literature and also to
other documents and resources (e.g. local regulations)
available to experts. Since for the majority of reviewed
procedures no formal recommendations were available,
the experts had to reach the consensus with regard to
proposed recommendations. As a result, optimal safety
measures for various procedures have been proposed.
This consensus, which is based on the recommenda-
tions of international experts, provides useful informa-
tion for allergy specialists and all doctors who diagnoses
and treat allergy patients. Moreover, the consensus has
value for general allergy practice worldwide; thus WAO
is an appropriate organization to provide it.
The following grading of recommendations on the
safety measures has been presented based on the con-
sensus reached by the expert panel:
A. Mandatory
B. Recommended
C. Suggested
D. non-required
Recommendations reported in the sections below have
been summarized in Table 1 and 2.
Diagnostic procedures
Skin testing for inhalant and food allergens – Skin Prick
Test (SPT) and Intradermal Skin Test (IDST)
Skin testing with inhalant and food allergens
Definition and short technical description These in
vivo tests are used for the detection of allergen specific
IgE on the skin mast cells and confirmation of
sensitization to a specific allergen [1].
Skin Prick Test (SPT)
Skin prick testing relies on the introduction of a very
small amount of allergen extract into the epidermis
using a disposable fine needle or lancet device, which is
changed with each test allergen [2]. Besides metal de-
vices, there are other varieties of commercially available
skin prick devices. The incorporation of these devices
into the protocol may require prior evaluation [3]. Skin
prick should be applied carefully, as insufficient prick
may produce false negative results, and induction of
bleeding (too deep) may produce false positive results
and bear the risk of systemic reactions. Allergens should
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be placed at least 2 cm apart to avoid overlapping re-
sponses between allergens tested. The results of skin
prick testing are read at 15 min and the diameter of the
resulting weal is recorded in two dimensions (longest
and its orthogonal diameter). By convention, a positive
test is one in which the mean of the two weal diameters
Table 1 Summary of Safety Recommendations for Diagnostic Allergy Procedures (for details, see the text)
Section subtitle Recommended
site
Emergency
equipment
availability
Emergency staff (ICU)
availability
Duration of
supervised follow-up
in the office after
procedure
Comments
Skin testing (SPT and IDST)
With Inhalant and
food allergens
Both O and H (a) mandatory (c) not required 20 min Field skin testing (prick test only), for
epidemiology studies, may also be
carried out by trained medical
personnel.
Skin testing with
hymenoptera venoms
Both O and H (a) mandatory (c) not required 20 min
Skin testing with
drugs
O or H depending
on the risk
assessment
(a) mandatory
Comment: not
applicable for
patch testing
available on site (a) or
available within 30 min (b)
depending on the risk
assessment
20 min Patients at risk: Patients who are
tested for anaphylactic reactions, or
with a history of complicating
conditions such as asthma,
mastocytosis and severe cardiac
disease
Skin testing with
occupational
allergens
Both O and H (a) mandatory (c) not required 20 min
Skin testing with
latex
Both O and H (a) mandatory (b) available within 30 min 20 min For some patients waiting time
should be extended to 40 min
Bronchial challenge
with allergen
Both O and Ha (a) mandatory (b) available within 30 min 7 h aalthough outpatient clinic is
acceptable the hospital setting is
recommended
Bronchial challenge
with lysine aspirin
(Lys ASA BPT)
Both O and H (a) mandatory (b) available within 30 min 1 h
Nonspecific bronchial
provocation tests
(NS-BPT)
Both O and H (a) mandatory (c) not required not required
Nasal allergen
provocation tests
Both O and H (a) mandatory (b) available within 30 min 30 min
Nasal aspirin
provocation tests
Both O and H (a) mandatory (b) available within 30 min 30 min
Nasal endoscopy Both O and H (d) not required (c) not required not required unless
complications occur
Food challenges Both O and H (a) mandatory (a) available on site or (b)
available within 30 min,
depending on risk
assessment
1-2 h after negative
and 4 h after
positive food
challenge
Oral drug
provocation test
O or H depending
on risk assessment
(a) mandatory (a) available within 5 min,
or (b) available within
30 min, depending on risk
assessment
at least 2 h;
hospitalization is
recommended after
severe reaction
Insect sting challenge Both O and H (a) mandatory (b) available within 30 min at least 2 h until
symptoms have
disappeared
O: Outpatient clinic
(a) mandatory
(b) recommended
(c) suggested
(d) not required
H: Hospital setting
(a) available on site (in less than 5 min)
(b) available within 30 min
(c) not required
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is at least 3 mm greater than the negative control (sa-
line) [4]. Positive and negative controls are critical to en-
able interpretation of test results. Ideally, the histamine
control is read at 10 min. The test is usually performed
on the volar aspect of the forearm but it is also per-
formed on the back, especially in young children. There
is a gradient of response when using the back – with lar-
ger responses in the lower third compared to the upper
third [5]. Interpretation of results should consider the
following factors: the allergen extracts used (standard-
ized when available), the type of lancet device, the skin
site chosen for testing, the clinical state of the patient
and the medications used by the patient.
Intradermal allergy testing (IDST)
Intradermal allergy testing is a procedure where a
small amount of diluted allergen is injected into the der-
mis. It increases the sensitivity but decreases the specifi-
city of the test and is carried out with allergen
concentrations 100 to 1000 times less than that used for
skin prick tests. It has no place in aeroallergen (other
than for research) and food allergen testing. It is most
commonly used in testing for drug and venom allergy.
Clinical indications SPTs may be used for the evalu-
ation of allergen-specific IgE to inhalants, foods, drugs
and venom in the following conditions: respiratory/in-
halant allergy, food allergy, venom allergy, drug
allergy.
IDSTs have a very high non-specific reaction rate
and are not recommended for testing with inhalants
or foods [6] and food allergens [7]. Moreover, intra-
dermal tests carry a higher risk of adverse reactions
than SPTs.
Age limitation Testing can be performed from infants
to the elderly. Infants and the elderly have smaller SPT
weal responses, and prominent flare responses [8].
Description of adverse/unintended reactions associated
with the procedure SPT is considered a safe procedure,
with minimal discomfort. Adverse events can occur but
rarely. These are classified as allergic or non-allergic.
1. Type and spectrum of unintended allergic reactions
 Local:
In some patients with marked sensitivity late
phase local skin swelling (the IgE late phase
Table 2 Summary of Safety Recommendations for Therapeutic Allergy Procedures (for details, see the text)
Section subtitle Recommended
site
Emergency
equipment
availability
Emergency Staff (ICU) Availability Duration of supervised
follow-up in the office
after procedure
Comments
Subcutaneous
immunotherapy
with inhalant
allergens
Both O and H (a) mandatory (a) available on site (in less than 5 min),
or (b) available within 30 min, depending
on risk assessment and the immunotherapy
protocol used
30 min
Venom
immunotherapy
Both O and H (a) mandatory (b) should be available on site, (in less
than 5 min) or within 30 min, depending
on the risk assessment and the
immunotherapy protocol used
30 min
Drug
desensitization
procedures
O or H
depending on
risk assessment
(a) mandatory (a) available on site (in less than 5 min) 30 min after acute
reactions
Waiting time can be
extended to 24-98 h
for delayed reactions
Oral
immunotherapy for
food allergy
Both O and H (a) mandatory available within 5 minutess (a) or
available within 30 min (b) depending
on risk assessment
2 h Currently not
recommended for
routine clinical use
Treatment with
Anti-IgE and other
biologicals
(a) mandatory (b) available within 30 min 2 h for the first
administration;30 min
for succesive
administration
Treatment with
products from
human plasma
(a) mandatory (b) available within 30 min 30 min
O: Outpatient clinic
(a) mandatory
(b) recommended
(c) suggested
(d) not required
H: Hospital setting
(a) available on site (in less than 5 min)
(b) available within 30 min
(c) not required
Kowalski et al. World Allergy Organization Journal  (2016) 9:33 Page 4 of 42
response) consisting of tender and painful
swelling may occur (seen more commonly with
intradermal testing). Rarely, it could cause quite
marked swelling and discomfort, but does not
usually last more than 36 h [9].
 Systemic:
Systemic reactions associated with SPTs, usually
starting within 15 to 30 min, have been reported
as case reports [10], in surveys and in prospective
studies. Although systemic reactions may occur
in any individual undergoing skin testing (both
adults and children), specific risk factors should
be taken into consideration when performing
these tests (see section III).
 Fatal Reactions:
Few fatal reactions as a result of skin testing have
been described in the literature [11, 12]. Based on
two large retrospective surveys by the American
Academy of Allergy and Immunology in the US,
seven fatalities have been described involving
older children and adults. Six of these deaths
involved intradermal testing to inhalants and food
and one death involving skin prick testing
performed with 90 allergens.
2. Type and spectrum of non-allergic reactions.
These may include syncope (vasovagal syncope)
and headache, Based on a prospective study in
children [13] and a retrospective survey [11], all
reported systemic and vasovagal syncope reactions
related to skin testing occurred within 15 to 30 min
of the test.
3. Prevalence and risk associated with the procedure.
The prevalence of systemic reactions related to skin
prick testing with inhalant and food allergens is low
but not absent. It was estimated to be less than
0,055 % [14, 15]. The rate of systemic reactions
requiring epinephrine was reported as 20 per
100,000 SPT visits [16]. The prevalence in young
children appears to be higher with a reported rate of
systemic reactions of 0.12 % [13] and 6.5 % in
infants less than 6 months of age [17].
4. Risk factors for adverse/unintended reactions
 Systemic Reactions: [7, 9, 11, 12, 17]
– Infants especially <6 months
– Multiple allergens
– Previous history of anaphylaxis to food when
testing for incriminating food
– Testing with fresh food (non-commercial
extracts)
– Testing with non-standardized latex extracts
– Extensive eczema
– Uncontrolled asthma
– Intradermal Testing
– Vasovagal syncope [13]:
– Female sex
– Testing with multiple allergens
Institutional/organizational safety recommendations
Several guidelines for performing skin tests have been
published:
 Allergy diagnostic testing: an updated practice
parameter (Bernstein et al, 2008) [18]
 Skin Prick Testing for the diagnosis of allergic
diseases – A manual for practitioners
(Australasian Society of Clinical Immunology and
Allergy, 2013) [9]
 Allergic Rhinitis and its Impact on Asthma;
Practical guide to skin prick tests in allergy to
aeroallergens. Allergy 2012;67:18-24 [19].
WAO safety recommendations These recommenda-
tions are based on the rare occurrence of severe systemic
reactions reported in retrospective surveys, one pro-
spective study, and several case reports. Quality of evi-
dence is high regarding the rare occurrence of systemic
life threatening and fatal (1 case in the literature with
skin prick test without intradermal test) reactions justify
the need for facilities offering skin prick testing to have
the following prerequisites for safety. There are no rec-
ommendations for intradermal testing as they are not
indicated for inhalant and food testing [20].
1. Site:
 Both a hospital and outpatient clinic setting
 Field (skin prick test only), e.g. epidemiology
studies, may also be carried out by trained
medical personnel.
2. Personnel:
Can be performed by trained nurse/technician
under supervision of experienced physician
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
Not required
5. Pretreatment:
Not applicable
6. Duration of supervised follow up after the
procedure:
It is recommended that patients who have
undergone skin prick testing and have positive
results, who have asthma or a history of anaphylaxis,
should remain in the centre for at least 20 min
following completion of the skin prick test [9].
7. Contra-indications:
Contraindications to skin prick testing may be
categorized into:
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 Clinical situations which interfere with the
procedure or its interpretation. These include
absence of normal skin, including
dermatographism, use of medication that might
inhibit skin prick responses.
 Relative contraindications related to safety/high
risk situations. These include severe or unstable
asthma and patients on beta-blockers. If SPT is
considered to carry a significant risk e.g. in a
highly sensitized patient or in a woman with
unstable asthma in pregnancy then avoid
performing the test.
8. Other considerations:
In patients with a history of anaphylaxis, skin prick
tests should be initiated with several serial 10-fold
dilutions of the usual test concentration.
Skin testing with hymenoptera venoms
Definition and short technical description Immediate
hypersensitivity skin testing is performed with standard
techniques and standard reporting of results. Venom
skin testing may begin with prick/puncture tests using a
venom concentration of 1,0- 100 mcg/ml, or with intra-
dermal tests using venom concentration of 0.001 -1
mcg/ml. If the puncture test is negative, it is followed by
an intradermal test using venom concentration of 0.01
mcg/ml. If the intradermal test using venom concentra-
tion of 0.01 mcg/ml is negative, it is repeated using con-
centrations of 0.1 mcg/ml, and then if necessary 1.0
mcg/ml. A positive puncture test has a wheal diameter
at least 3 mm larger than the diluent (negative) control.
Intradermal tests should introduce sufficient volume to
give a 3–4 mm bleb (usually 0.02–0.03 ml). A positive
intradermal test has a wheal diameter of at least 5 mm.
Clinical indications Skin tests for venom allergy are in-
dicated to confirm the presence of venom sensitization
in patients who have had systemic reactions to insect
stings (or repeated severe large local reactions) and are
candidates for venom immunotherapy. Testing is also
useful to distinguish among different types of venom
(bee, wasp, etc);
Age limitation No age limitation.
Description of adverse/unintended reactions associated
with the procedure Adverse events are very rare with
venom skin tests. Local itching and induration is a nor-
mal positive response, and may take hours to subside.
Anaphylactic reaction to venom skin tests is extremely
rare. Unintended consequences of venom skin tests can
occur when the tests are performed in individuals who
have no clear history of anaphylaxis to a sting. This is
because venom skin tests can be positive in 15–20 % of
adults, and in more than 30 % of those who have been
stung in the previous few months. A positive test in such
individuals creates the perception of risk even when the
history might indicate low risk (<3 %) of anaphylaxis.
This is the case in people who have large local reactions
to stings, in those with only cutaneous systemic reactions
to stings, and in patients who have completed a 5 year
course of venom immunotherapy.
1. Type and spectrum of adverse reactions
 Local:
Local adverse reactions are very uncommon but
might cause delayed progressive swelling and
induration of the test site, with itching and
possibly pain.
 Systemic:
Systemic allergic reactions to venom skin tests
are rare, and near-fatal or fatal reactions are
exceedingly rare.
2. Prevalence and risk associated with the procedure:
Early studies of venom skin tests included small
numbers of subjects. They were focused on
diagnostic accuracy, and reported no significant
adverse effects. The only large study reporting on
the safety of venom skin tests was that of Lockey et
al [20]. In that survey of 3236 patients, 64 (2 %) had
a systemic reaction during venom skin tests, 13
(0.4 %) of which were severe. Thirteen of 64 adverse
reactions (20 %) were possibly vasovagal, and six
other subjects (9 %) demonstrated no symptoms of
immediate-type hypersensitivity. Thus, 45 (1.4 %) of
the 3236 subjects tested had a systemic reaction that
was considered to be a reaction of hypersensitivity,
of which eight reactions (0.25 %) were severe.
3. Risk factors for adverse/unintended reactions:
The risk of severe anaphylaxis is always increased in
patients with a history of asthma. The severity of the
previous reaction to a sting is not a risk factor for
anaphylactic reaction to skin tests. In contrast to
skin tests with inhalant allergens, the risk of
anaphylaxis is not increased when intradermal tests
are performed without initial prick/puncture tests.
In fact, there are 2 studies of “accelerated” venom
skin tests that reported no increased risk of adverse
reaction [21, 22]. Guidelines and Practice Parameters
in Europe and the United States do not recommend
any precautions for venom skin tests in patients who
are taking beta-blockers of ACEI medications.
Institutional/organizational safety recommendations
Guidelines and Practice Parameters in Europe and in the
United States do not express any concern about safety of
venom skin tests, and do not recommend any specific
precautions or safety measures [19, 18, 23].
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WAO safety recommendations
1. Site:
Both outpatient clinic and hospital setting
2. Personnel:
Tests are performed by personnel who have
undergone training and proficiency testing. A
physician should be present.
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
Not required
5. Pretreatment:
Not applicable
6. Duration of the supervised follow up after
procedure:
20 min
7. Contra-indications:
See contraindications for SPT in previous section
(inhalants)
8. Other considerations:
The results of venom skin tests must be reviewed
and interpreted by an experienced specialist in
allergology, in the context of the clinical history of
the patient and the natural history of the condition.
The pitfalls of diagnostic allergy testing have been
well-described [24].
Skin testing with drugs
Definition and short technical description Skin Prick-
(SPT) and Intradermal Skin Tests (IDST) are the most
useful modality for demonstrating an IgE-mediated
mechanism underlying clinical symptoms [25], whereas
epicutaneous patch testing (or SPT/IDST with delayed
reading) is the logical first step in defining the relevant
drug in delayed cell-mediated hypersensitivity to system-
ically administered drugs – and not only for contact
dermatitis caused by topically applied drugs [26, 27].
However, depending on factors such as the clinical type
of reaction, the drug suspected, the pathomechanism of
the reaction, the availability of qualified test substances
and the existence of a valid test protocol, an individual
approach must be chosen for any specific situation, i.e.
drug testing has to be performed in an individualized
manner.
Generally it is advised to perform the tests 6 weeks to
6 months after the hypersensitivity reaction. SPT can be
done with any soluble drug, for the IDST sterility is im-
portant. Patch tests can be performed with any form of
commercial drugs. In general, for most of the drugs
there is a lack of standardization of reagent concentra-
tions. Only recently a guideline has been released listing
all the published and recommended test concentrations
for any drug reported [28].
Clinical indications Indications for SPT and IDST with
drugs are immediate reactions manifested as erythema-
tous eruptions/flushing, urticaria and angioedema, ana-
phylaxis, conjunctivitis, rhinitis and bronchospasm/
asthma. The most common use of patch testing with
drugs are maculopapular exanthemas, acute generalized
exanthematous pustulosis (AGEP), and fixed drug erup-
tions [29, 30]. Other clinical entities where patch tests
are being used are delayed-appearing urticaria, photo-
sensitivity, drug reactions with eosinophilia and systemic
symptoms (DRESS/DIHS), Abacavir hypersensitivity syn-
drome, Stevens-Johnson syndrome and toxic epidermal
necrolysis (TEN) [31].
Age limitation Skin testing with drugs can be per-
formed at any age, although the experience in children is
limited.
Description and prevalence of adverse/unintended
reactions associated with the procedure Skin testing
with drugs is a safe diagnostic approach, if performed
according to the published guidelines [26, 28, 32, 33].
However tests may be associated with some risk of ad-
verse local and also systemic reactions; a relapse of the
previous reaction might be provoked with any skin test
procedure.
1. Type and spectrum of adverse reactions:
 Local:
SPT, IDST and patch tests may cause local
irritation resembling (false-) positive reactions.
Skin necrosis and scarring might result from
testing with toxic substances such as
chemotherapeutic agents or when using non-
physiological concentrations.
 Systemic:
Anaphylaxis after SPT with chymopapain,
penicillin, tetanus toxoid, and other drugs, has
been reported rarely, leading to the conclusion
that SPT is a safe diagnostic procedure, although
a theoretical and remote risk in principle remains
[10].
– IDST, being more sensitive than SPT, is more
likely to induce systemic reactions. Urticaria, and
rarely anaphylaxis have been described almost
exclusively with β-lactams [reviewed in 25].
– Systemic reactions associated with patch testing
are extremely rare. In a retrospective study that
evaluated 111 and 134 patients with a history of
severe cutaneous adverse reactions to drugs no
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severe side effects induced by the tests were
reported [27, 30].
 Flare-up reactions:
Flare-up reactions might be mediated by IDST
and patch tests. A patch test-induced exfoliative
dermatitis was observed in a patient with an ad-
verse reaction to carbamazepine [34]. A relapse
of a pruritic rash occurred following a prick test
with pristinamycin [35]. The relapse of an
AGEP has been provoked by patch testing with
acetaminophen (paracetamol) while these tests
remained negative [36]. Thus, patch tests, SPT,
and IDST can induce a systemic reaction even
though their results were negative [26].
 Fatalities:
The few fatalities associated with skin tests,
reported from 1895 to 1980, were associated with
biologic products that are no longer used such as
horse serum-derived tetanus or diphtheria toxins
or pneumococcal antiserum [reviewed in 29]. A
recent literature review on systemic reactions
from skin testing concluded that the occurrence
of systemic reactions with inhalant allergens has
diminished over the last 30 years, whereas fresh
food, hymenoptera venom and antibiotic SPT still
carry some risk [10].
 Risk factors for adverse reactions:
In general, patients with history of previous
anaphylactic reactions, uncontrolled asthma or
high degree of reactivity, small children or
pregnant women,, may be considered at higher risk
(i.e., they may react more readily and/or more
severely to the minute test amounts applied [25].
Institutional/organizational safety recommendations
Several guidelines for performing drug skin tests have
been published [26, 28, 32, 33].
WAO safety recommendations
1. Site:
SPT and IDST with drugs should be performed in
hospital settings of specialized centers. Since adverse
reactions to drug patch testing are rare and rather
not severe, tests can be applied at outpatient clinics.
2. Personnel:
Trained technician or nurse under supervision of a
physician. Personnel has to be prepared, trained and
equipped for serious events, especially anaphylactic
reactions.
3. Emergency equipment availability:
Should be available on site (mandatory) for SPT and
IDST. Not applicable for patch testing.
4. Emergency staff (ICU) availability:
Should be available on site (mandatory) – only for
patients who are tested for anaphylactic reactions, or
for patients with a history of complicating
conditions such as asthma, mastocytosis and severe
cardiac disease.
For all other patients should be available within
30 min
5. Pretreatment:
Not applicable
6. Duration of the supervised follow up for safety after
the procedure:
Should remain in the centre for at least 20 min after
completion of the procedure. After IDST in patients
with previously diagnosed asthma (due to the
suspected drug itself or as an underlying disease)
supervised follow-up should be extended to 6 to
8 h [25].
7. Contraindications:
Drug-induced autoimmune diseases, severe
exfoliative skin reactions and severe vasculitis
syndromes for SPT and IDST [25]. There are no
absolute contraindications for patch testing with
drugs.
See also contraindications for SPT in previous
section (inhalants)
Skin testing with occupational allergens
Definition and short technical description The tech-
niques for skin test (ST) with occupational allergens are
identical to ST with other (inhalant) allergens. As for
other allergens, in routine the skin prick test (SPT)
should be preferred over the intradermal skin test
(IDST), because it causes less pain and there is a lower
risk of systemic reactions. Since there is no clear defin-
ition of occupational allergens (also food and drugs are
occupational allergens for some workers) for the purpose
of this document we looked for potential adverse reac-
tions after skin testing in occupational exposed workers.
The following sensitizing substances most commonly
cause occupational asthma and are used for skin testing:
dust of cereal flours, enzymes, laboratory animals, farm-
ing (animals, cereals, hay, straw and storage mites), fish
and seafood as well as low molecular substances such as
isocyanates, platinum salts and acid anhydrides [37, 38].
Natural rubber latex (hereinafter referred to as latex) is
discussed separately (see following section on skin test-
ing with latex). Due to the fact that occupational aller-
gies in comparison to sensitizations to ubiquitous
allergens are rare, often no standardized SPT solutions
are available. In these cases non-standardized patient-
tailored allergen preparations have to be used. If the pa-
tient shows a positive reaction to such a SPT solution,
control tests should be performed in a number of
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healthy subjects in order to exclude an unspecific
reaction.
Clinical indications For the diagnosis of occupational
type I allergies, the common steps are a detailed case
history, skin testing, in vitro diagnosis (mostly specific
IgE antibodies), and specific inhalation challenge. The
clinical indication for SPT with occupational allergens
(including latex) is to demonstrate IgE-mediated
sensitization to occupational allergens. However, in com-
bination with work-related symptoms of the patient, SPT
with occupational allergens is also relevant for compensa-
tion and further socioeconomic consequences.
Age limitation In general, STs with occupational aller-
gens are performed only in working adults.
Description and prevalence of adverse/unintended
reactions associated with the procedure Taking into
account, that skin tests with occupational allergens are
only performed in adults and that commercial ST solu-
tions for occupational allergens (other than latex) usually
contain only small amounts of antigens and proteins
[39] ST and especially SPT with occupational allergens
remains a safe diagnostic procedure.
1. Type and spectrum of adverse reactions
 Local:
If non-standardized patient-tailored allergen
preparations are used, local adverse reactions
might be caused by irritation or toxic reaction
 Systemic:
In general the risk of systemic reaction following
ST with occupational allergens is low (lower with
SPT than IDST). There exists one report about
an anaphylactoid reaction (without cardiovascular
symptoms) after a scratch test with iridium
chloride in an occupational exposed process
operator [40]. However, scratch tests have generally
been abandoned because of non-standardized
procedure.
 Fatal:
Out of 17 cases of anaphylaxis after SPT with
various allergens listed by Liccardi [10] after
Medline research (1980-2005) none referred to
occupational exposure.
2. Risk factors for adverse reactions:
Unknown
Institutional /organizational safety recommendations
EAACI position paper: skin prick testing in the diagnosis
of occupational type I allergies [41]
WAO safety recommendations Although allergy ST is
considered a safe procedure, it is not without risk of sys-
temic reaction
1. Site:
Both outpatient clinic and hospital setting
2. Personnel:
Can be performed by trained nurse/technician under
supervision of experienced physician
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
Not required
5. Pretreatment:
Not applicable
6. Duration of the supervised follow up after
procedure:
Should remain in the centre for at least 20 min after
completion of the procedure
7. Contra-indications:
Identical to ST with other (inhalant) allergens
8. Other considerations:
None
Skin testing with latex
Definition and short technical description Natural
rubber latex (NRL), commonly referred to as latex, is a
vital natural resource that is used in the manufacturing
of a wide variety of commercial products ranging from
airplane tires to protective medical gloves. Ninety-nine
percent of latex comes from one source: the sap-like fluid
from the rubber tree Hevea brasiliensis. Sensitization to
latex, which is a potent allergen, affects people who are
frequently exposed to products made of latex such as
health care and latex industry workers, patients with a his-
tory of multiple surgical procedures including children
with spina bifida as well as specific food allergy patients.
Fourteen latex allergens have been identified and skin
test (ST) extracts have to contain especially NRL allergens
Hev b 1, 2, 3, 4, 6.01, 7.01, and 1 and recombinant Hev b
5 (rHev b 5). Skin prick test (SPT) should be performed,
intradermal tests are not recommended (Cabañes et al.
2012) [42]. SPT extracts to determine latex allergy in-
cluded commercial extracts, latex glove extracts and hevea
leaves. Serial 10-fold dilutions of non-ammoniated latex
(NAL, e.g. from Malaysian Hevea brasiliensis (clone 600)
sap (Greer Laboratories)) or newly introduced ammoni-
ated latex (AL, e.g. Bencard Laboratories, Mississauga,
Ontario) allergens were employed in ST. Standardized ex-
tracts can provide a sensitivity of 93 % with a specificity of
100 % [42].
Also ‘glove use tests’ are performed. Considerable dis-
parity exists between glove use protocols, with exposure
times ranging from 15 min to 2 h. In general, the first
Kowalski et al. World Allergy Organization Journal  (2016) 9:33 Page 9 of 42
step involves placing a fingertip of the glove on a damp-
ened finger; if the result is negative, the complete pow-
dered glove is put on. A vinyl or nitrile glove is used on
the other hand as a negative control. The result is con-
sidered positive if contact causes erythema, pruritus,
blisters, or respiratory symptoms [42].
Clinical indications Latex is a common component of
many medical supplies used in the hospital environment.
Although latex is most often associated with disposable
gloves, other items which may contain latex are breath-
ing tubes, infusion sets, syringes, stethoscopes, catheters,
dressings and bandages. Frequent users of latex products
may develop a latex allergy. Allergic rhinitis and asthma
mainly affect individuals exposed via inhalation, such as
health care workers, lab workers, dentists, nurses, and
physicians.
Patients at risk are also subjects with spina bifida and
congenital genitourinary abnormalities who have under-
gone multiple procedures. While the incidence of latex
allergy in the general population is 1 % to 2 %, in spina
bifida (SB) patients, who are mostly children, incidence
of latex allergy ranges from 20 % to 70 % [43]. As well,
people who have certain food allergies, including ba-
nana, avocado, chestnut, apricot, kiwi, papaya, passion
fruit, pineapple, peach, nectarine, plum, cherry, melon,
fig, grape, potato, tomato and celery, may also have signs
of a latex allergy due to cross-reactivity.
Diagnosis of latex allergy is based on clinical suspicion.
A good clinical history taken by an experienced allergol-
ogist is very important. The history should record the
presence or absence of other allergies, atopy, previous
operations or medical procedures involving latex prod-
ucts, reactions induced by ingestion of fruits and
whether the patient belongs to a risk group. The com-
plementary diagnosis is based on STs and the determin-
ation of specific IgE [42].
Age limitation SPTs with latex are performed both in
adults and children.
Description and prevalence of adverse reactions
associated with the procedure Skin testing with latex
allergen is associated with a significant risk of adverse
systemic reactions
1. Type and spectrum of adverse reactions
In most cases, subjects with adverse reactions after
latex SPT showed a variety of different symptoms.
 Local:
There are no reports about isolated large local
reactions after latex SPT. One health care
worker in whom angioedema, hives and
hypotension developed had no discernible
wheal and flare reaction at the site of the SPT
(Kelly et al. 1993) [44].
 Systemic:
Several reports of anaphylaxis during SPT for latex
allergy have been published (Table 3). However, in
these former cases mostly non-standardized SPT
extracts prepared from powdered latex gloves or
crude latex preparations directly from Hevea brasi-
liensis trees were used. In a study initiated with the
goal to establish an FDA (Food and Drug
Table 3 Exemplary cases of systemic reactions during skin prick test (SPT) with latex
Number
of cases
reported
Type of ST Culprit agent (type of latex) Symptoms/fatalities Reference Comments (e.g. setting, age etc.)
1 SPT Liquid latex material Immediate flushing, tachycardia,
urticaria, light-headedness
Spaner et al. 1989 [260] 34 year old female Operating
room nurse
1 SPT 10 % aqueous dispersion Cold, sweaty extremities, initial
tachycardia, subsequent
bradycardia, hypotension
Bonnekoh and Merk
1992 [261]
17 year old female dentist’s
assistance
1 SPT 100 HEP Hevea brasiliensis Dizziness, difficulty with breathing,
wheezing, tachypnoea
Nicolaou and Johnston
2002 [262]
39 year old female house wife
6 SPT extemporaneous extracts
(dilutions of 1:1000, 1:100,
and 1:10) (n = 5), commercial
SPT solution (n = 1)
Signs of anaphylaxis in different
degrees
Nettis et al. 2001 [48] 6 female patients with age
ranging from 26-51
9 SPT 1:100,000 dilution of latex
glove extract
Systemic reactions Kelly et al. 1993 [44] 9 of 107 patients: 85 children
with spina bifida, 15 health care
workers, 7 others
2 or 3a SPT 50 % glycerine, 0.23 mg/mL
total protein from gloves
Pruritus, flushing, urticaria,
angioedema, asthma, cough chest
tightness, wheezing, dyspnea, eye
itching, nasal congestion
Valyasevi et al. 1999 [15] 2 or 3a patients from a clinic out
of 1316
ain one patient reason of anaphylactic reaction was not clear because he was also positive to aeroallergens
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Administration) – licensed extract for use in the
United States an optimal diagnostic
accuracy (SPT [IDST]: sensitivity 96 % [93 %],
specificity 100 % [96 %]) without any systemic
or large local reactions was obtained in 59 latex
allergic adults with a non-ammoniated latex ex-
tract (SPT 100 μg/ml, IDST 1 μg/ml) [44]. More
recently, the available standardized latex SPT
reagents in Canada and Europe enable SPT with
latex with a low risk of inducing systemic aller-
gic reactions [45, 46]. However, so far there is
no approved SPT solution for latex in the United
States [47]. Not only SPT with latex per se is
mentioned to be a putative risk factor for ana-
phylaxis during SPT but also a low age [9].
 Fatal:
The authors did not find reports that patients
died after latex SPT. However, in cases of
anaphylactic reactions emergency
pharmacologic intervention was necessary [48]
and patients have been hospitalized for
continued therapy [44].
2. Prevalence and risk factors for adverse reactions
Young patients with spina bifida may be at higher
risk of systemic reactions with latex SPT. As a rule,
patients with a positive bronchial challenge test
result presented the most severe reactions [48]. It
has been suggested that in patients with a history of
latex allergy with systemic symptoms in-vitro tests
should be performed before SPT [44].
Institutional/organizational safety recommendations
There are no published safety recommendations refer-
ring specifically to skin testing to latex allergens. The
currently published position paper ‘Latex Allergy’ stated
that standardized latex SPT extracts are considered safe,
although isolated cases of anaphylaxis have been reported.
Intradermal tests are not recommended [42]. The diag-
nostic algorithm for latex allergy which has been proposed
by Hamilton et al. [46] may decrease the risk of adverse
reactions during skin testing.
WAO safety recommendations Skin testing with latex
allergens in highly sensitive patients is considered to be
associated with some risk of systemic reactions.
1. Site:
Both hospital and outpatient setting
2. Personnel:
Should only be conducted by allergy specialists or
equivalently trained medical nurse/technician
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
Should available within 30 min
5. Pretreatment:
Not applicable
6. Duration of the supervised follow up after
procedure:
Time of supervised follow-up should be extended up
to 40 min.
7. Contra-indications:
Patients with a history of systemic reactions due to
latex: no latex SPT or safety precautions essential
8. Other considerations:
In patients with a history of latex allergy with systemic
symptoms in-vitro tests should be performed before
SPT. To reduce the likelihood of adverse reactions
SPTs with latex allergen should be performed using
different dilutions (beginning with higher dilutions).
See also contraindications for SPT in previous
section (inhalants)
Bronchial provocation tests (BPTs)
Bronchial provocation tests with allergen
Definition and technical description Inhalation or
bronchial allergen challenge is a well-established and re-
producible method to confirm sensitization to specific
allergen in the bronchi. Allergen-induced reaction mani-
fests as an early asthmatic response (EAR) and may or
may not be followed by a more prolonged airway re-
sponse (late asthmatic response; LAR).
Two methods can be used: continuous generation of
an aerosol by a nebulizer and inhaled by the subject via
a facemask or inhalation of a standardized dose of an
aerosol by generating it intermittently. Any reproducible
inhalation method can be used for either approach, the
incremental allergen challenge usually employs 2-mins
tidal breathing from a calibrated constant output nebulizer,
while the single bolus method usually uses a counted num-
ber of deep breaths from a (breath-actuated, standard-dose)
dosimeter [49, 50]. Both methods produce comparable
airway responses.
The patient can also be challenged with allergen
(e.g. wheat flour), with a use of a special/custom
chamber, by the allergen as such especially in exami-
nations for occupational asthma (e.g. baker’s asthma)
[51] or in environmental exposure chambers for clin-
ical research purposes. Bronchial response to allergen
is either early, late or both and is verified by measur-
ing lung volumes (FEV1) by flow-volume spirometry
or peak expiratory flow (PEF) values. The patient is
closely followed for at least 6 to 8 h after the chal-
lenge. In some centers segmental bronchial provoca-
tion techniques through fibro-optic bronchoscope
have been employed.
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Clinical indications Allergen challenge is not a routine
diagnostic procedure as patients are examined for their
asthma or asthma suspicion and asthma diagnosis is ob-
tained by other means. BPT with allergen is primarily a re-
search tool in investigations on pathophysiology of asthma
and on asthma controller therapy. However in some cen-
ters BPT with allergen is used to confirm sensitization
and/or explain discrepancy between the clinical history,
and the sensitization (skin tests and specific IgE).
Allergen provocation is also done to explore the
causal relationship of allergen exposure at a work-
place to patient’s actual symptoms (occupational
asthma) [51]. For example, in the Finnish clinical rou-
tine these tests are rarely performed and only in oc-
cupational settings.
Age limitation In clinical allergy practice inhalant aller-
gen tests are seldom done to children or elderly, how-
ever no clear age limits have been established. Adults of
working age are usually subjects of these tests, especially
in occupational settings or research. There are centers
where children are challenged with allergen (e.g. house
dust mite) [52, 53].
Description of adverse/unintended reactions
1. Type and spectrum
 Local:
Bronchoconstriction is developing from few
minutes to 3 h and patient usually experiences
some cough, chest tightness and even wheezing.
These symptoms are usually easily to control
with bronchodilators. From 16 to 50 % of the
patients, dyspnea may appear after 3 to 8 h as a
LAR [54].
Severe asthma attack resulting in prolonged
exacerbation of asthma sometimes occur. Other
accompanying local symptoms may include
irritation of throat, trachea and bronchi, causing
cough.
 Systemic:
Exceptionally, severe anaphylactic reactions
caused by the allergen inhalation challenges can
occur. Such reactions usually develop within few
minutes and require epinephrine injection.
 Fatal reactions:
One case of death caused by rapid, severe
bronchoconstriction and anaphylaxis have been
reported during exposure to isocyanate 30 years
ago [53].
2. Prevalence
No systematic review is available on the occurrence
of unexpectedly strong bronchial responses or
anaphylactic reactions. For occupational allergen
inhalation challenge it is considered that 12 %
required repeated administration of an inhaled
short-acting bronchodilator, while few (3 %, 95 % CI:
1–5 %) induced an asthmatic reaction that required
additional oral or IV corticosteroids [55].
3. Risk factors
Unstable asthma (FEV1 below 70 %, recent
hospitalization for asthma requiring oral corticosteroids).
The risk of moderate or severe reaction was
increased when the subjects were challenged with a
LMW agent and when they were using treatment
with an inhaled corticosteroid [55].
Institutional/organizational safety recommendation
Safety recommendations have been included in the state
–of-the art documents published by the ERS/ATS,
EAACI, or the French Society of Allergology [56].
WAO safety recommendations
1. Site:
Hospital setting recommended. Outpatient clinic
setting could be acceptable.
2. Personnel:
The provocation test can be performed by a trained
nurse/technician but only under the surveillance of a
competent physician.
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
Should be available within 30 min
5. Pretreatment:
Is not necessary, but symptoms of positive reaction
should be immediately relieved by the inhalation
of short-acting b2-agonist or by nebulization
(e.g. 2.5–5.0 mg of salbutamol). In case of more
severe reactions oral or intravenous corticosteroids or
epinephrine are administered.
6. Duration of the supervised follow up after
procedure:
The patient should be followed closely in a hospital
setting for at least 7 h after provocation. The subject
should never be left unattended during and
following the challenge procedure and FEV1 should
be closely monitored for at least 7 h post-challenge.
After the last lung function measurement (usually
at ≥ 7 h post-challenge), subjects should receive
inhaled bronchodilators until the FEV1 returns
within approx. 10 % from pre-allergen baseline.
Only if this is achieved and the subject is clinically
stable, subject can be sent home with the following
precautions: secured transportation from research
center to home address, provided with rescue
medications, preferably not left alone at home, and
emergency number(s) of on-call qualified physician
who has been notified of the subject.
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7. Contra-indications for BPT with allergen
 Uncontrolled asthma and /or FEV1 < 70 % of
predicted
 Recent hospital admission or asthma
exacerbation
 Spirometry-induced bronchoconstriction (i.e., less
than 2 baseline FEV1 measurements out of 8
attempts within 15 %);
 Recent major surgery; severe disease of the heart,
brain, digestive tract, liver, kidney
 Active, recent or chronic infections;
immunological disorder; cancer, history of
anaphylaxis
 Pregnancy
 Use of systemic beta-blockers
8. Other considerations:
Allergen preparations employed in the challenge
should be as standardized as possible. Furthermore,
to prevent sensitization and/ or bronchoconstriction
in sensitized investigators, an exhaust hood and/or
(HEPA) filters should be used during allergen
nebulization.
Other GCP-based prerequisites relate to data quality
and integrity, consist of:
 Adequate, well-ventilated challenge rooms with
standardized humidity conditions within an
irritant and smoke-free area,
 Regularly calibrated and serviced equipment
meeting ATS/ ERS criteria,
 Standardized, validated SOPs,
 Qualified laboratory and pharmacy, complying to
locally required standards.
Bronchial provocation with lysine-aspirin
Definition and short technical description Bronchial
challenge with a soluble form of aspirin (lysine – aspirin;
L-ASA) is used to confirm a history of hypersensitivity
reactions induced by aspirin or other NSAIDs in patients
with an underlying chronic airway respiratory disease
(asthma/rhinosinusitis/nasal polyps) and manifesting pri-
marily as bronchial obstruction, dyspnea and nasal con-
gestion/rhinorrhea [57]. Incremental concentrations of
L-ASA are administered by a dosimeter-controlled jet-
nebulizer in 30 min intervals and forced expiratory vol-
ume in 1 s is measured at 10, 20 and 30 min after each
dose [58, 59]. The provocation is considered positive if
at least 20 % fall in FEV1 as compared with post saline
baseline value occurs [60]. Diagnostic inhalation chal-
lenges with other NSAIDs (indomethacin, sulpyrine,
ketoprofen) have been also reported.
Clinical indications An inhalation provocation test with
lysine -aspirin is used to confirm hypersensitivity to
aspirin or other NSAIDs in patients with cross-reactive,
respiratory type of hypersensitivity. It is an alternative to
oral aspirin challenge test which is the diagnostic gold
standard, but brings some risks of systemic reaction (see
section on Oral Drug Provocation Test). Inhalation test
with L-ASA is faster to perform than the oral test, but it
is less sensitive and negative result of an inhalation test
does not exclude NSAIDs-hypersensitivity. The diagnos-
tic value of L-ASA BPT has been documented only in
patients with a history of respiratory type of hypersensitiv-
ity to ASA/NSAIDs - called Aspirin Exacerbated Respira-
tory Disease (AERD) or NSAIDs Exacerbated Respiratory
Disease (NERD) - and is considered to be specific, repro-
ducible, and generally safe method for NERD confirm-
ation [61].
Age limitation The test is usually performed in adults
since NERD is rarely seen in children. However, a single
study on L-ASA BPT challenges in children (aged 6–17
years) reported, similar to adults, general safety of this
procedure [62]. Interestingly, in one child, urticarial
symptoms were reported following L-ASA bronchial
challenge.
Description of adverse/unintended reactions associated
with the procedure
1. Type and spectrum of adverse reactions
1. Local:
Typical and expected symptoms include dyspnea
and chest tightness accompanied with fall in
FEV1 developing within 10–30 min after positive
bronchial challenge. The symptoms can be easily
relieved by inhaled/nebulized β2 agonist. In some
patients an early prolonged reaction has been
observed (fall in FEV1 developing with 2–3 h)
[63], while in one study, several hours following
lysine aspirin challenge the development of late
bronchial symptoms was observed [64].
2. Systemic:
Bronchial reaction induced by inhalation of
L-ASA may be accompanied by extrabronchial
(nasal and/or cutaneous) symptoms in almost
half of ASA-hypersensitive patients, and in some
patients, inhalation of L-ASA results in
development of isolated extrabronchial
symptoms [65, 66]. Only a single case of severe,
systemic reaction has been described in a patient
with history of ibuprofen - induced dyspnea, but
without typical asthma triad [67]. The reaction
alter LysASA BPT started with facial flush, and
generalized pruritus was followed by shortness of
breath, cold sweating, and wheezing. Severe
bronchoconstriction (75 % fall in FEV1) was
associated with asphyxia and
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hypotonia. The patient fully recovered after
administration of epinephrine, oxygen, a short acting,
bronchodilator by inhaler, methylprednisolone, and
volume expander.
3. Fatal reaction:
No fatal reaction has been reported
2. Prevalence and risk associated with the procedure:
Although BPT with L-ASA is generally safe, it may be
associated with systemic reaction, thus precautions
during the procedure are necessary. The major risk is
a significant bronchospasm, which however, can be
easily relieved by appropriate treatment [68].
3. Risk factors for adverse reactions
Low basal FEV1 (below 70 % of predicted),
uncontrolled asthma, inappropriate increasing of the
dose of inhaled Lys-aspirin.
Institutional/organizational safety recommendations
General safety recommendations has been presented by
the HANNA/ENDA guideline [57]
WAO safety recommendations The following WAO
safety recommendations are proposed (Grade IV):
1. Site:
4. Hospital or outpatient clinic setting
2. Personnel:
 Physician should be responsible for supervising
the L-ASA bronchial challenge procedure, which
may be performed by a nurse.
3. Emergency equipment availability:
 Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
 Should be available within 30 min
5. Pretreatment:
 Is not necessary, but symptoms of positive reaction
should be immediately relieved by the inhalation
of short-acting b2-agonist or by nebulization
(e.g. 2.5–5.0 mg of salbutamol). In case of more
severe reactions oral or intravenous corticosteroids
or epinephrine are administered.
6. Duration of the supervised follow up after procedure:
 Patient should remain under observation in the
office/hospital for at least 1 h after the
completion of an aspirin inhalation challenge.
The FEV1 value should have returned to within
10 % of the prechallenge baseline, before
discharge from the hospital. The patient should
be provided with a peak expiratory flow (PEF)
meter and record the PEF values before leaving
the hospital and every 2–3 h until late evening. In
the case of any respiratory symptoms and a 20 %
decline in PEF value, the patient should take
short acting β2-mimetic and contact the center.
7. Contra-indications:
 Uncontrolled asthma and/or FEV1 below 70 %
of predicted
 A history of very severe anaphylactic reactions
precipitated by aspirin or other NSAIDs
 Infection of respiratory tract within 4 weeks
prior to the challenge
 Recent major surgery, severe disease of the
heart, brain, digestive tract, liver, kidney
 Pregnancy
 Use of systemic beta-blockers
8. Other considerations
 Although associated with some risk of more
severe reaction, Lys-ASA-BPT is generally
considered safe, sensitive, specific and reliable
diagnostics tool for confirming both AERD and
NERD
Nonspecific bronchial provocations
Definitions and technical description During NS-BPT,
a patient inhales under laboratory conditions increasing
doses (concentrations) of a potentially bronchospasm-
inducing agent or is exposed to forced hyperventilation
during exercise. After inhalation of each dose FEV1 is
measured. A challenge is completed when a significant
fall in FEV1 occurs or a maximal cumulative dose (con-
centration) is administrated. The stimuli used for non-
specific BPT can be classified as direct (methacholine,
histamine, leukotrienes or prostaglandins), and indirect
(e.g. exercise, eucapnic voluntary hyperpnea, hypertonic
saline, adenosine monophosphate, and mannitol) de-
pending if they act directly on a specific airway smooth
muscle receptor or release mediators from inflammatory
cells [69–71].
Clinical indications The test are used to confirm the
presence or assess the degree of airway hyperrespon-
siveness, which is one of the main characteristics of
asthma, and its measurement, using different
methods, is important in establishing a correct diag-
nosis [72]. However, non-specific airway hyper re-
sponsiveness may be also present in other chronic
respiratory conditions such as COPD, cystic fibrosis,
or allergic rhinitis. These tests have been also used to
monitor asthma treatment [73] and to monitor non-
specific bronchial hyperresponsiveness before and
after bronchial challenges with specific occupational
and non-occupational agents [74].
Age limitations Since change in FEV1 is the primary out-
come measure for these tests, the ability to perform reliable
spirometric maneuvers is the major limitation. Therefore,
the use of these testing methods is not recommended for
those under the age of 6. There is no upper age limit to
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perform NS- BPT. The use of impulse oscilometry, instead
of spirometry, may expand the age groups able to perform
reliable spirometric maneuvers as it requires passive co-
operation instead of active participation [75].
Description of unintended/adverse reactions associated
with the procedure
1. Type and spectrum of adverse reactions
 Local:
Cough is the most common side effect of these
protocols [71]. Less common side effects include
oropharyngeal pain and irritation, chest
discomfort, and dizziness. There are isolated
cases of angioedema and Vocal Cord Dysfunction
reported in the literature. Clinical staff exposed to
the bronchoprovocation agents are at increased
risk of bronchospasm if they have asthma.
 Systemic:
No systemic reactions except for cough or gag
have been reported.
 Fatal:
No fatal reactions following NS-BPT have been
reported.
The NS-BPT procedures are considered to be
generally safe and adverse reactions are usually
mild and fairly easy to control. Most patients re-
cover spontaneously after the challenge test or after
receiving a standard dose of a bronchodilator. Dis-
tressed
patients respond very well to inhaled bronchodilators
with or without oxygen supplementation.
2. Risk factors for adverse reactions/unintended reactions
The risk of excessive reaction may be increased in
individuals with low baseline lung function, if their
asthma is not well controlled or during active
respiratory infection.
Institutional/organizational safety recommendations
Both European and America guidelines propose safety
measures and list contraindications for NS-BPTs [76–78].
WAO safety recommendations and contraindications
1. Site:
Hospital or outpatient clinic setting – These
procedures do not require hospital-based specialized
centers and hospital admission is not necessary for
the duration of the provocation [79].
2. Personnel:
The procedure can be performed by trained
technician/nurse who is familiar with the guidelines
and knowledgeable about specific test procedures.
Physicians who have expertise in the field should be
readily available to manage acute asthmatic reactions
or other complications.
3. Emergency equipment available:
Should be available on site (recommended)
4. Emergency staff (ICU) available:
Not required
5. Pre-treatment:
No pre-treatment is necessary, however drugs
which may potentially affect the reactions (see
guidelines) should be withheld prior to the chal-
lenge [80].
6. Duration of supervised follow-up:
Due to the characteristics of the agents used,
late-phase reactions are not expected, except in rare
cases after exercise tests. As a result, no special
follow-up is needed after recovering from
bronchospastic reactions.
7. Contraindications:
 Severe airflow limitation (FEV1, < 50 % predicted
or < 1.0 L) (absolute contraindication)
 Moderate airflow limitation (FEV1 < 60 %
predicted or <1.5 L(relative contraindication)
 Uncontrolled asthma
 Spirometry-induced bronchoconstriction (i.e., less
than 2 baseline FEV1 measurements out of 8
attempts within 15 %);
 Recent major surgery; severe disease of the heart,
brain, digestive tract, liver, kidney
 Active, recent or chronic infection
 Pregnancy
 Use of systemic beta-blockers
 Current use of cholinesterase inhibitor
medication (for myasthenia gravis) for
methacholine challenges
8. Additional for exercise testing:
The European Respiratory Society suggested [80]:
 FEV1 greater than 75 % of the predicted normal
value
 The patient with unstable cardiac ischemia or
malignant arrhythmias should not be tested.
 Those with orthopedic limitation to exercise are
unlikely to achieve exercise ventilation high
enough to elicit airway narrowing.
 For patients over 60 years of age, a 12-lead elec-
trocardiogram (ECG) obtained within the past
year should be available.
9. Other considerations:
 Subjects should understand the procedure and
be able to perform reliable spirometric
maneuvers.
Nasal provocation tests
Nasal allergen provocation tests
Definition and short technical description Nasal aller-
gen provocation test (NAPT) or nasal allergen challenge
test is the method by which the nasal mucosa is
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challenged by instillation of allergen into the nasal cav-
ities. NAPT assesses the nasal response to the suspected
triggering allergen.
There are several methods by which NAPT is per-
formed. Some clinicians perform it by spraying the aller-
gen solution as aerosols into the nasal cavity, while
others apply a small allergen coated paper disk on the
inferior turbinate. Nebulization or instillation by pipette/
dropper are other forms of NAPT. Yet another form of
allergen challenge is by using special challenge chambers
with controlled environments and precise delivery of
agents [81]. Therefore, there is no standardized uniform
method for performing NAPT, and so also for the pre-
cise criteria for evaluating the positive response, and
grading for the risk of adverse events [82, 83].
Clinical indications NAPT is performed to confirm the
diagnosis of AR in the situation of discrepancy between
the symptoms and the results of skin prick test (SPT)
and/or serum specific immunoglobulin E (sIgE), to object-
ively assess disease severity and to monitor the response
to pharmacologic treatment, for specific immunotherapy
(SIT) in AR, to study the pathophysiological mechanisms
of allergic inflammation, and to diagnose occupational
rhinitis [84]. Nasal provocation tests are necessary for the
diagnosis of local allergic rhinitis [85].
Age limitation NAPT can be done in both adults and
children. Upper age limit depends on the presence of
contraindicating disease conditions.
Description and prevalence of excessive/adverse
reactions associated with the procedure
1. Type and spectrum of excessive/adverse reactions
 Local:
– The chance of side effects is influenced by the
concentration of allergen and by the method
of allergen application. The appropriate dose
of allergen for provocation can be estimated
based on the dose of SPT. The dose of allergen
that elicits a positive response (3 mm) of SPT
can be used for NAPT. The starting dose can
be 1:1,000 then increased by either factor of 3
or 10 [86, 87] NAPT performed by spraying
allergen or applying a small disk on the inferior
turbinate carries a lower risk as compared to
the methods using nebulization or instillation of
allergen solution by a pipette/dropper.
– Adverse reactions from NAPT can be divided
into those upper airway reactions (mainly
nasal) and lower airway reactions
(bronchoconstriction). An excessive reaction
of the upper airway due to NAPT is a severe
nasal blockage or excessive nasal discharge.
NAPT also carries a risk of a delayed reaction
defined as the reappearance of nasal symptoms
3–12 h after NAPT [86, 88, 89]. Some
researchers have reported that the immediate
and late phase response of NAPT was 63 %
and 37 %, respectively [90].
– Lower airway adverse reaction to NAPT
(bronchoconstriction) can occur when the
allergen enters directly into the lower
respiratory tract via the larynx. The chance of
allergens directly entering the lower airways
also depends on the method of NAPT used.
 Systemic:
No systemic reactions following NPTs have been
reported
2. Risk factors for adverse reactions
The possibility of excessive/adverse events of NAPT
comes from either the use of excess allergen for
NAPT or deposition of the allergen from nose/
nasopharynx into the lower airways.
Institutional/organizational safety recommendations
Not available
WAO safety recommendations
1. Site:
Outpatient clinic or hospital setting
2. Personnel:
Technician/nurse with physician’s supervision
3. Emergency equipment availability:
Emergency equipment should be available on site
(mandatory)
4. Emergency staff (ICU) availability:
Should be available within 30 min
5. Pretreatment:
Not applicable
6. Duration of the supervised follow up after
procedure:
30 min
7. Contra-indications:
 Intense nasal obstruction or septal perforation
 Current nasal symptoms
 Within 4 weeks after viral or bacterial infection.
 Not well-controlled asthma, severe asthma or severe
chronic obstructive pulmonary disease (COPD)
 Cardiopulmonary disease where epinephrine is
contraindicated
8. Other considerations:
Proper cooperation of the patient when performing
NAPT (especially when performing by allergen
nebulization or pipetting/dropping) is mandatory.
The patient should hold one’s breath during allergen
instillation to prevent the leaking of the allergen into
the lower airways [91, 92].
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Nasal aspirin provocation
Definition/description Nasal challenge with lysine as-
pirin or ketorolac (United States) can be used to diag-
nose aspirin exacerbated respiratory disease (AERD).
Baseline symptoms and measurements of the upper and
lower airway are made and then incremental doses of
the aspirin or NSAID are applied internally to the nose,
as drops or spray with close monitoring of symptoms
and airway measurements. The timing of response differs
from allergen challenge- so 45 min is allowed between ap-
plication and measurement. An increase in nasal symp-
toms (obstruction, rhinorrhea, sneezing, itching) plus an
objective decrease in the upper airway of >25 % minimal
cross sectional area or volume 0–12 cm on acoustic rhi-
nometry is a positive response [60, 93].
If negative after a total of 150 mg lysine aspirin an oral
challenge should be undertaken.
Clinical indications Used to assess aspirin sensitivity in
patients with rhinitis and/or polypoid rhinosinusitis, and/
or asthma.
Age limitation Usually done in adults since AERD is
uncommon in children. Upper age limit depends on
health status, particularly spirometry- see below. Avoid
in pregnancy.
Description of adverse/unintended reactions associated
with the procedure
1. Local:
Since topical aspirin is applied to possibly sensitive
tissue the reaction usually involves the upper airway
first with predominant symptoms being nasal
obstruction, rhinorrhoea, sometimes sneezing,
itching. The lower airway may become involved,
with asthma symptoms, but this is less frequent than
with oral challenge and rarely severe. Laryngospasm
reported following ketorolac challenge. About 5–10 %
of subjects experience mild gastric irritation.
2. Systemic:
Very rarely skin reactions such as urticaria and
angioedema can occur, again less commonly than
with oral challenge where some 25 % are affected.
3. Fatal:
No fatalities have been reported using nasal aspirin
challenge
4. Risk:
Using nasal lysine aspirin the challenge dose can be
very accurately controlled. 6 % of 131 subjects
developed asthma symptoms, only 1.5 % showed a
significant >20 % decrease in FEV1. Skin reactions
occurred in 5.3 %, mainly urticaria, one patient
developed facial angioedema [94]. Compared with
the standard oral aspirin challenge and
desensitization, intranasal ketorolac and modified
aspirin challenge significantly attenuated the mean
percentage decrease in FEV(1) values (8.5 % vs
13.4 %; P = .01) and decreased the percentage of
extrapulmonary reactions (23 % vs 45 %; P = .002),
particularly laryngospasm (7 % vs19%; P = .02) and
gastrointestinal reactions (12 % vs 33 %; P = .001).
This protocol was significantly shorter, lasting an
average of 1.9 vs 2.6 days (P = <.001). In fact, 83 % of
the patients completed the new protocol in less than
48 h compared with only 20 % in the oral challenge
control group (P < .001) [93].
5. Risk factors for excessive reactions:
 Laryngospasm to aspirin-challenge inadvisable
 Failure to monitor nasal airway objectively
 Dose miscalculation
Institutional/organizational safety recommendations
EAACI/GA2LEN guideline: aspirin provocation tests for
diagnosis of aspirin hypersensitivity [60].
WAO safety recommendations
1. Site:
Both hospital and outpatient clinic setting
2. Personnel:
Technician/nurse supervised by physician
3. Emergency equipment availability:
Should be available on site (suggested).
4. Emergency staff (ICU) availability:
Available within 30 min
5. Pretreatment:
Pre-treatment with all usual asthma therapy on day
of study permitted; nasal therapy stopped one week
beforehand.
6. Duration of the supervised follow up after
procedure:
30 min
7. Contra-indications:
History of anaphylactic to NSAIDs Other
contraindications as listed in previous section (NPT)
8. Other considerations:
 Informed consent is mandatory.
 In very severe aspirin hypersensitivity, for safety
reasons start with lowest dose.
 Use of acoustic rhinometry to monitor nasal
airway is recommended (Nasal Inspiratory
PeakFlow is less sensitive) [95].
Nasal endoscopy
Definition and short technical description
Nasal endoscopy is the gold standard and the most valuable
tool in the clinic to afford the diagnosis (presence, severity,
etiology, and follow-up) of the majority of rhinologic
pathologies [96–98].
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Nasal endoscopy is performed by a flexible or rigid
scope attached to a light source by glass fiber. For diag-
nostic examination, a scope with an optic angle from
0–45° is used with a caliber of 2,5–4 mm. Other optics
(45–70°, 4 mm) are mostly used in surgery. Nasal en-
doscopy may eventually be preceded by local adminis-
tration of anaesthetic and/or decongestive drugs. First,
the bottom of the nose through the nasopharynx is to
be inspected with an evaluation of the nasal septum,
the lower turbinate and meatus, the choanae and the
nasopharyx. Afterwards, the scope follows the edge of
the middle turbinate towards the rostrum sphenoidale,
with examination of the middle and upper turbinates,
the mucus drainage from the sinuses, possible accessory
ostia from the maxillary sinus, and the aperture of the
sphenoidal sinus. At last, to get a view of the ostiomeatal
complex, the ethmoidal bulla, the access to the frontal
sinus, and the olfactory cleft must be attempted.
Clinical indications
The following reasons for nasal endoscopy can be con-
sidered in allergy practice:
 The physical examination of the nasal cavities and
paranasal sinuses. The different structures of the nose
can be evaluated: nasal septum, upper, middle and
lower turbinates and meati, ostiomeatal complex,
cavum, nasopharynx, and olfactory cleft. Even
oropharynx and larynx can also be examined using
flexible endoscopy. Although subjective in nature
(physician interpretation) it can provide an objective
evaluation of nasal signed (i.e. nasal congestion,
rhinorrhea/postnasal drip). Despite being more
difficult to perform, rigid nasal endoscopy usually
provides a better examination view than flexible
endoscopy and anterior rhinoscopy [99].
 To assess severity, and to follow-up (after medical or
surgical treatment) of nasal and sinusal diseases
[97, 98, 100, 101]:
 For differential diagnosis of sinus diseases e.g.
– Structural abnormalities: septal deviation,
turbinate hypertrophy, choanal atresia, or
adenoid hypertrophy.
– Nasal vasculitis, granulomatosis, or bleeding diseases.
– Benign tumors and malignancies (unilateral
versus bilateral)
 To obtain biopsies (i.e. nasal mucosa, nasal polyps,
tumors) and microbiological samples for both
disease diagnosis and translational research [99].
Age limitation (children, adults, elderly)
Nasal endoscopy is possible in all ages, including chil-
dren [99, 102]. The only relative limitation is the lack of
patient’s collaboration.
Description of adverse/unintended reactions associated
with the procedure
1. Type and spectrum of adverse reactions:
Nasal endoscopy adverse reactions are mainly local.
When exploring the nasal cavities a very mild
discomfort with sensation of foreign body, nasal
itching, and sneezing is quite common. Contact of
endoscope head with the nasal mucosa, mainly
linked to some unexpected patient head sudden
movement, can induce some burning or pain
sensation and rarely minor epistaxis. Although
possible, vasovagal reactions are very uncommon.
When exploring the throat with flexible scopes, a
nausea sensation can also be induced. There is no
data in the literature reporting prevalence and risks
associated with the nasal examination using nasal
endoscopy.
2. Risk factors for unintended reactions:
Non-compliant patients, mainly children, and
patients with significant nasal septum deviations
and/or risk of epistaxis constitute the relative risk
factors for these adverse reaction.
Institutional/organizational safety recommendations
Both European (European Rhinologic Society [ERS],
European Academy of Allergology and Clinical Immun-
ology [EAACI]) and American (American Academy of
Otolaryngology, Head and Neck Surgery [AAOHNS],
American Academy of Allergy Asthma and Immunology
[AAAAI]) scientific societies have produced a number of
position papers which include the efficacy, safety, and
main technical recommendations for the use of nasal en-
doscopy in daily practice, clinical trials, and sinonasal
and skull base surgery [99, 103, 104].
WAO safety recommendations
1. Site:
Both hospital and outpatient clinics
2. Personnel:
Nasal endoscopic, either rigid or flexible, should be
performed by a well-trained physician, either
otorhinolaringologist or not (allergologist,
pneumonologist, pediatrician, or even general
practitioner).
3. Emergency equipment availability:
Not required
Comment: For potential minor epistaxis, a wet
gauze or merocel pack as well as silver nitrate sticks
for cauterization of potential minor nasal bleedings
should be available. For unusual but potential
vasovagal adverse reactions, a reclining chair or a
litter should be available in the clinic.
4. Emergency staff (ICU) availability:
Not required
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5. Pretreatment:
In general, no pretreatment is mandatory. If
examination is difficult to perform, bothersome
and/or painful, local anesthesia (lidocaine,
cocaine) may be used [105]. A nasal decongestant
may also be useful mainly in the presence of
nasal deviation, turbinate hypertrophy or swollen
mucosa. Both local nasal anesthesia and nasal
decongestion may help the physician to have a
better view of nasal cavities, turbinates, middle
meatus, and nasopharynx as well as to make the
patient feel more comfortable during the
endoscopic examination.
6. Duration of the supervised follow-up after nasal
endoscopy:
After nasal endoscopy, patients do not need a
special follow-up supervision. Only in the case of
minor complications (nasal bleeding, vasovagal
reaction) the patient may remain in observation in
the clinic as needed (usually less than one hour).
7. Contraindications:
There are no major contraindications for nasal
endoscopy. Minor contraindications may be severe
nasal hyperreactivity (can be solved by using local
anesthesia), non-collaborative patients, and
predisposition to nasal bleeding (nasal vasculitis or
granulomatosis, Rendu-Osler syndrome).
8. Other considerations:
The presence of nasal deviations, turbinate and
adenoid hypertrophy and chronic rhinosinusitis with
or without nasal polyps are usually considered as
exclusion criteria in clinical trials investigating the
effect of medications in allergic rhinitis. Since
posterior nasal deviation and small size nasal polyps
are not easily visualized using anterior rhinoscopy, a
number of patients with this concomitant problems
(10–15 % of general population has CRS and 4 %
nasal polyps) may be wrongly included in such
clinical trials.
Food provocation tests
Definition and short technical description
The oral food challenge (OFC) test involves having a pa-
tient ingest a food gradually, in incrementally increasing
doses, under medical supervision to determine if there is
allergy or tolerance [105–109]. The food may be pre-
pared and presented in the manner in which it is typic-
ally consumed, or its taste and texture may be masked
by mixing it with other foods. When the food is pre-
sented in its natural form, the test is considered an
“open” feeding. An open OFC is commonly used in clin-
ical practice [110], but may introduce bias. The food is
masked for single-blind or double-blind, placebo-
controlled OFCs, the latter format being considered the
least prone to patient and observer bias and is therefore
considered the “gold standard” [107, 111]. Testing is per-
formed when the patient is in good general health and
without flares of atopic disease, has eliminated the food
from their diet, is not using medications that interfere
with interpretation of the test (for example antihista-
mines), or medications interfering with gastric digestion
and threshold levels such as anti-ulcer drugs [112]. Pa-
tients are observed throughout the OFC, and the feeding
proceeds unless the clinician diagnoses an allergic re-
sponse. If a typical serving size of the food is ingested
without symptoms, tolerance is diagnosed. This may re-
quire an open feeding of a larger amount following a
masked feeding. If a reaction is elicited, treatments may be
administered to reverse the allergic reaction, and the con-
clusion is that the patient is allergic. The time required for
feeding the test substances (test food and placebo), and
observing for reactions, varies depending upon specific
protocol and the anticipated outcomes, e.g., immediate or
delayed reactions, but usually takes several hours.
Clinical indications
An OFC is indicated to confirm that an allergic or other
adverse reaction to a food exists [105–108, 113]. The
test is recommended as a diagnostic procedure because,
in contrast to a positive allergy skin or serum sIgE test
that indicates sensitization but is not solely indicative of
allergy, the OFC may verify or exclude clinical allergy
[111, 114, 115]. An OFC is typically administered when
other tests, including the medical history, skin testing
and/or serum tests are inconclusive, and there is motiv-
ation to add the food to the diet or clarify the existence of
the allergy [105]. Typical circumstances warranting an
OFC include: suspicion of an allergy because of a possible
allergic reaction, but having inconclusive supporting tests;
no exposure to the food but having positive tests, or evalu-
ating if an allergy has resolved when other tests remain in-
conclusive. The OFC test can detect immediate or delayed
allergic and even non-immunologic reactions. An OFC
may also be indicated for research purposes, or to deter-
mine an individual’s threshold of reactivity [107]. When
making the decision to perform an OFC, the clinician
should also consider the: risk of reaction (based on history
and prior tests), potential severity of a reaction (may relate
to the food tested, history, presence of asthma in the pa-
tient, test results), patient or family preferences, nutri-
tional importance of the food, social aspects of being able
to advance the diet, and emotional consequences should
the food not be tolerated.
Age limitation (children, adults, elderly)
The test may be conducted at any age. The test can in-
duce anaphylaxis; therefore, the physician should be
confident in recognizing and treating anaphylaxis in the
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age group being tested, and understand the health issues
that may increase adverse reaction risks or present con-
traindications in the age group tested (e.g., heart disease,
obstructive lung disease, pregnancy, etc.) [107, 108].
Description of adverse/unintended reactions associated
with the procedure
1. Type and spectrum of adverse reactions
A physician-supervised OFC may induce allergic
reactions that could range from mild to severe,
including anaphylaxis. Food-induced anaphylaxis can
be fatal [116]. Although severe reactions have been
documented [117, 118], fatal reactions during
supervised OFCs have not been reported.
Nonetheless, fatal reactions can occur. Symptoms
in the event of a reaction, which are expected and
should be anticipated, most commonly affect the
skin, followed by gastrointestinal and respiratory
symptoms [118, 119]. Cardiovascular symptoms
are uncommon but must be anticipated, especially
in adults. Delayed and biphasic reactions are
possible, but also uncommon [120].
2. Prevalence and risk associated with the procedure
The likelihood of having a reaction and the
severity of a reaction is not accurately predictable
by current tests [105–107, 109, 121, 122]. Data
regarding risk assessment is limited by biases
introduced by patient selection and other factors
(foods tested, age, clinical approach, definition of
a positive test, etc.). Variability in patient
selection likely accounts for the large range of
OFC outcomes; for example studies in children
report reaction rates of 19–48 % [111, 118, 120,
123]. The emotional impact, for example
increasing anxiety, is also not predictable.
Reactions are most often managed with
antihistamines, but epinephrine, including more
than one dose, may be needed [120]. Epinephrine is
administered, in general, for under 10 % of challenges
(overall challenges, including those without reactions)
[111, 120, 124]. Additional treatments may be
required (e.g., oxygen, intravenous fluids,
bronchodilators, etc.).
3. Risk factors for adverse/unintended reactions
It is presumed that risk factors for reactions include
increasingly positive test results, the food tested,
personal sensitivity and target organ reactivity (e.g.,
asthma) [105, 123]. Clinical decisions about stopping
an OFC, for example continuing dosing if a reaction
has not clearly occurred, but is suspected, may also
introduce increased risk that must be weighed
against benefits of confirming the allergy [105, 106].
Dosing amount, and frequency between doses, may
play a role in outcomes, but this has not been
systematically studied [105, 107, 125]. Reactions,
including severe ones, may occur on the first dose of
an OFC [119, 121]. Very slow and gradual dosing
does not necessarily reduce the risk of allergic
reaction severity [107, 125]. Using capsules to mask
the food allergen is not generally recommended. The
use of capsules may result in more severe or
uncontrolled reactions because they may release
allergen in an unpredictable fashion and also oral
symptoms are bypassed [126].
Institutional/organizational safety recommendations
A number of safety recommendations have been pro-
mulgated by various organizations, expert panels and au-
thors [105, 107, 113, 114].
WAO safety recommendations
1. Site:
Both hospital and outpatient clinic setting
2. Personnel:
Trained personnel, including a physician, with
experience in the procedure and skill
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
Should be available on site (in less than 5 min) or
within 30 min depending on the risk assessment
5. Pretreatment (if any):
Not applicable
6. Duration of the supervised follow up after
procedure:
Observation periods should be determined based on
clinical circumstances, but generally a 1–2 h
observation is suggested for patients who tolerate
the full food dose during the OFC and at least 4 h
when a significant reaction occurs; discharge
instructions should include the possibility of late
reactions (patients understand how to identify and
treat);
7. Contra-indications:
The test should not be performed when the food has
recently caused a life-threatening reaction or if the
patient has a chronic medical condition that would
pose a health threat in the event of anaphylaxis
(angina, cardiac disease, pregnancy, severe chronic
lung disease, use of beta-blockers, etc.).
8. Other considerations:
Recording a peak flow or spirometry may be
considered and intravenous access should be
secured if anaphylaxis or severe reactions such as
enterocolitis [127] are likely, or if emergency
intravenous access would be deemed difficult.
Monitoring of the blood pressure may be
necessary.
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It is important to select a starting dose that is likely
below the patient’s reaction threshold. Upon positive
food challenge the patient should be advised in
regard to dietary restriction through trained
personnel (e.g., dietician) and equipped with emergency
medications (e.g., self-injectable epinephrine) for
allergic reactions upon accidental exposure. Patients
should be encouraged to eat the food on a regular
basis after a negative test.
Oral drug provocation test
Definition and short technical description
Oral drug provocation test (DPT) is the controlled ad-
ministration of a drug to diagnose immune-mediated
(allergy) and non-immune-mediated drug hypersensitiv-
ity reactions. Incremental doses of the drug are adminis-
tered with the aim of inducing symptoms emulating
those reported by the patient but at a very low scale and
in a safe and controlled manner. DPT should be per-
formed placebo-controlled, single blinded, and, in situa-
tions where psychological factors may be present, even
double-blind. The rational approach is provided in dif-
ferent reviews [128–130] and protocols are published
for several drugs but these have not been standardized
[57, 61, 129, 131–135].
Clinical indications
DPT are usually performed if other less dangerous test-
ing methods are not available or do not allow a firm
conclusion, and the outcome is of clinical relevance to
the patient. DPT may be carried out in the following
situations:
 To confirm the presence of hypersensitivity in a
patient with equivocal history
 To exclude hypersensitivity, when clinical history
suggests it may not be the culprit drug, when the
reaction does not appear to be drug hypersensitivity
reaction, and when skin tests or in-vitro tests are
not available.
 To assess cross-reactivity to related drugs (e.g. an
alternative betalactam antibiotic or another COX-1
inhibitor in hypersensitivity to NSAID)
 To certify tolerance to an alternative drug
Age limitation
There is no data on the age limit for DPT. In general,
the procedure is limited by the ability to objectively as-
sess the supposed hypersensitivity reaction that may be
elicited and the risk to the patient when the reaction is
provoked.
Description of adverse/unintended reactions associated
with the procedure
The intention of the DPT is to evoke a hypersensitivity
reaction, however the magnitude of the reaction should
be limited to the minimum. Thus the major task is to
minimize the potential risk of development of general-
ized and/or severe reaction
1. Type and spectrum of adverse/unintended reactions
Adverse reaction is anticipated to be similar in
manifestations to those occurring in the
hypersensitivity reaction, with a similar time kinetic
but usually milder and of shorter duration. In
practice it may vary from mild, local and transient
to generalized and severe and in some instances
potentially fatal.
2. Prevalence and risk associated with the procedure
The prevalence and risk of adverse reaction is
dependent on the correct assessment of causality of
the hypersensitivity reaction, risk-benefit evaluation
of the patient undergoing DPT, assessment of the
general health of the patient on day of procedure,
and compliance with the technical requirements of
DPT [122, 124].
3. Risk factors for adverse/unintended reactions
Patients with severe co-morbidities such as
uncontrolled asthma, cardiac, hepatic, renal or other
organ specific or systemic diseases which can be
worsened or activated if the hypersensitivity reaction
is provoked would be at higher risk. In such
instances, DPT is considered only if the drug under
suspicion is essential for the patient.
Institutional/organizational safety recommendations
The most comprehensive safety guideline on DPT is from
the European Network for Drug Allergy (ENDA) [57].
Other guidelines are on the general aspect of the diagnosis
and management of drug allergy [18, 62, 136–138].
WAO safety recommendations
General statement All DPT must be preceded by an in-
dividual risk-benefit assessment [139].
1. Site:
 Both hospital and outpatient clinic setting
 DPT can be done in the clinic setting if previous
reaction was mild [140]. Patients with more
severe reactions should be hospitalized for DPT
[128].
2. Personnel:
DPT should only be carried out by a trained nurse/
technician under the direct supervision of the
allergist.
3. Emergency equipment availability
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Should be available on site (mandatory)
4. Emergency staff (ICU) availability
Should be available on site (within 5 min) or within
less than 30 min reach depending on the risk
assessment.
5. Pretreatment
 There should not be any pre-treatment that may
mask early signs of a reaction.
 H1-antihistamines should be discontinued
(duration depending on the half-life of the
preparation) before the procedure. Corticosteroids,
anti-leukotrienes and tricyclic antidepressants
may modify response to the challenge and should
be reviewed. Medications that may cause problems
if emergency treatment becomes essential e.g. ß-
blocking agents have to be reviewed and decision
made on whether to stop the drug prior to DPT
[141].
6. Duration of the supervised follow up after procedure
The duration of supervised follow-up after procedure
is dependent on the expected time latency between
drug ingestion and reaction onset based on the
previous hypersensitivity episode. In general,
immediate-type reactions need a short observation
period, whereas delayed-type reactions in the history
may necessitate similarly long observation periods
after procedure. If a mild reaction has occurred
during DPT, observation after stabilization is
recommended for at least 2 h. After severe reactions,
hospitalization is mandatory because of the possibility
of biphasic episodes that can be lethal if not
recognized early and treated adequately [142]. It is
recommended that before going home, all patients
are given an action plan that stresses when to seek
medical attention and a number to call in case of
emergency.
7. Contraindications:
DPT should not be carried out when the
hypersensitivity reaction is serious and potentially
life-threatening including: anaphylaxis, drug
hypersensitivity syndromes/drug reaction with
eosinophilia and systemic symptoms, acute generalised
exanthematous pustulosis, exfoliative dermatitis,
erythema multiforme major/Stevens-Johnson
Syndrome or toxic epidermal necrolysis, generalised
bullous eruptions, vasculitis and other drug-induced
autoimmune disease, or specific major organ
involvement such as cytopenia. Pregnancy is
considered a contraindication for DPT unless the drug is
essential during pregnancy or delivery [128, 137, 143].
8. Other considerations:
 On the morning of the DPT, the patient should
have had only a light breakfast and morning
medications taken or omitted (as instructed by
the attending allergist). The patient’s health status
should be good, without any sign of allergy or
viral infection. Blood pressure, pulse rate, peak
flow meter reading (in asthmatics or when
bronchospasm is anticipated), and intravenous
cannula inserted (if the initial reaction was
suggestive of a systemic reaction/anaphylaxis).
 Prior to each incremental provocation dose,
blood pressure, pulse rate, peak flow meter
reading (in asthmatics or if bronchospasm
anticipated), and any new symptom/sign must be
clearly recorded.
Insect sting challenge
Definition and short technical description
Sting challenge (SC) is the ultimate standard for the
diagnosis of insect venom allergy [144, 145]. During this
procedure patient is deliberately stung by a living insect
of the culprit species. Before SC the respective insect
needs to be entomologically classified.
In general, a blinded, placebo-controlled procedure is
not possible and incremental doses of culprit venom
cannot be applied, making the SC test less controllable
compared to other challenge tests in allergic patients. A
thorough patient work-up and the evaluation of contra-
indications are, therefore, of eminent importance.
Clinical indications
Depending on the individual risk profile and culprit, in-
sect venom immunotherapy (VIT) may not be effective
in 5–20 % of the patients. SC aims to identify those indi-
viduals on maintenance VIT to assess effectiveness and
who are not protected after 3–5 years of VIT. Although
the standard management of insect venom hypersensi-
tivity does not include SC in the United States [25, 146],
the results of SC tests may help physicians to decide on
whether VIT should be performed with a higher venom
dose and are an invaluable research tool. If standard VIT
is not effective (systemic allergic reaction at SC despite
VIT), a higher maintenance venom dose will be used
(usually 200 μg venom). Later on, VIT effectiveness may
be re-evaluated by a subsequent, second SC (after the
higher maintenance dose has been reached).
Additionally, results of SC may improve patient quality
of life if it can be demonstrated that one does not de-
velop an allergic reaction to a sting of the culprit insect
(i.e., less anxiety about future sting reactions).
Age limitation
There is no age limit for SC. However, in patients who are
not capable of understanding the procedure, and who can-
not give their informed consent SC cannot be done.
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Description of unintended/excessive reactions associated
with the procedure
1. Type and spectrum of unintended/excessive
reactions at sting challenge:
Adverse reactions include pain at sting site, and
local reactions which may be large. In case of
VIT failure, systemic allergic reactions may occur
varying between minor and very severe, and
affecting respiratory and/or cardio-circulatory
function.
2. Prevalence and risk associated with the procedure:
Pain at sting site, and a minor local reaction (wheal,
erythema, and swelling) is undesirable but is viewed
as a normal sting reaction. Large local reactions with
a diameter of more than 10 cm, and/or local
reactions of a duration of up to several days are
very rare. According to pooled data of
observational or randomized studies systemic
allergic reactions may occur in 18.0 % (range
0–59 %) of bee honeybee venom allergic patients
and in 4.3 % (range 0–12.3 %) of yellow jacket
(vespid) venom allergic patients [146]. The vast
majority of systemic reactions are mild to
moderate; however, cases of severe systemic
allergic reactions and in the absence of an early
efficient emergency therapy, even a fatal
anaphylactic reaction have been described.
3. Risk factors for unintended/excessive reactions:
 Systemic reactions need to be accepted in order
to identify treatment failure [147]. The general
risk for the patient in terms of a life-threatening
reaction is significantly lower in a medical setting
when adequate treatment of symptoms is started
immediately after first onset of symptoms, than at
field sting. In patients on VIT, several factors
determine the overall risk for a systemic allergic
reaction at SC (thereby indicating VIT failure).
Patients allergic to honeybee venom are at a
higher risk for systemic allergic reactions than
patients allergic to vespid venom [148–151].
Systemic allergic reactions during SC are also
more likely in patients who are on ACE
(angiotensin converting enzyme)-inhibitor therapy
[53–150, 152, 153]. The rate of systemic allergic
reactions at SC depends on the venom doses
applied during VIT with higher therapeutic venom
doses (individual or cumulative) decreasing this
rate [148, 151, 154]. The risk-lowering effect of a
higher therapeutic venom dose is not specific for
the type of Hymenoptera venom used for VIT.
Thus, during SC, the magnitude of risk reduction
is the same irrespective whether the patient has
received a double VIT (standard dose of two
different venoms), or a double dose of the same
venom [151]. Duration of VIT is inversely
correlated with the risk for a systemic allergic
reaction during SC [151]. Severe systemic allergic
reactions which have been observed before SC
during the build-up or maintenance phase of VIT
are also associated with an increased risk for a
systemic allergic reaction during SC [151, 154–156].
In addition, certain underlying diseases (mastocytosis)
increase the risk for systemic reactions at SC
[151, 157].
 Factors, which influence the severity grade of a
sting reaction, have not been systematically
investigated. However, mastocytosis is a clear risk
factor for very severe sting reactions [157].
Finally, the severity of systemic allergic reaction
will increase if the patient presents with severe
co-morbidities such as asthma or cardiovascular
diseases.
Institutional/organizational safety recommendations
Guidance on how to perform SC has been described,
and a guideline was published by the Interest Group on
Insect Venom Allergy of the EAACI [144, 158].
WAO safety recommendations
The patient must be screened for any contraindication
to SC; risks, benefits and alternatives of the procedure
shall be discussed with the patient, and written informed
consent for the procedure must be obtained. If the pa-
tient is unstable (in case of an organ dysfunction), or if
the patient requires a medication possibly disposing him
to a higher risk, SC shall be postponed until conditions
have been improved.
Drugs, which might ease symptoms of an allergic reac-
tion (thereby evoking falsely negative results at SC)
should be discontinued before SC. These drugs may in-
clude corticosteroids, H1-antihistamines, or anti-IgE
antibodies. The respective half-life of the medication has
to be considered when planning a SC. If an ACE-
inhibitor therapy is indispensable it should not be dis-
continued just because a SC is planned. ß-blocking
agents should be stopped prior to SC if possible.
Before SC, treatment protocols (indicating venom
doses of at least 100 μg, and adherence to injection
intervals) should be requested from patients who have
been treated elsewhere. Patients should remain fasted
for at least six hours before SC, and should not be on a
medication potentially interfering with anaesthesia.
Chronic diseases like asthma or arterial hypertension
should be stable and the patient should not suffer from
any relevant acute disease. Blood pressure, pulse rate,
and, in asthmatics, pulmonary peak flow or FEV1 should
be measured. Before SC, a peripheral intravenous
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cannula with a large bore should be inserted into all
patients.
1. Site:
 Both hospital or outpatient clinic setting
 After SC, some patients will require a subsequent
in-hospital surveillance or treatment. Therefore,
SC should be performed at a site which is
sufficiently close to a hospital specialized on
emergency treatment.
2. Personnel:
The insect can be put onto the patients’ skin and
can be motivated to sting by a trained nurse or by
other assistance personnel. SC shall be done under
direct supervision of an allergist.
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
Should be available within 30 min
5. Pretreatment:
No specific pretreatment is necessary.
Cardiovascular or bronchial diseases, which might
represent a specific risk in the context of SC, should
be treated to reach a stable situation.
6. Duration of the supervised follow up after procedure:
Monitoring of all subjective or objective signs and
symptoms is required during and after SC. After SC
the patient should be monitored for at least two
hours or longer, depending on the patient’s history
and on the outcome of SC. After severe systemic
allergic reactions, hospitalization is mandatory until
complete recovery (minimum duration 24 h).
7. Contraindications:
SC should not be done in patients who already
had a systemic allergic reaction after a field sting
while still being in the maintenance phase of VIT.
In patients with repeated side effects during the
maintenance phase of VIT, SC should not be
performed unless a tolerance of VIT has been
reached. Severe or poorly controlled
cardiovascular/respiratory diseases (FEV1-value ≤
70 %) as well as pregnancy are contraindications
for SC.
If medications which might lower the risk for
systemic allergic reactions at SC cannot be safely
withdrawn, they shall be continued. However, results
of subsequent SCs must be interpreted with caution
since there is an increased chance for falsely
negative results, and the reaction to a later field
sting may differ from that observed after SC.
8. Other considerations:
For patients with mastocytosis and other risk factors
an alleviated maintenance dose should be given from
the start.
Therapeutic procedures
Subcutaneous Allergen Specific Immunotherapy (SCIT)
Definition and technical description of the procedure (SCIT)
Since the beginning of the twentieth century, allergenic
vaccines were administered subcutaneously (SCIT). The
favorable clinical results obtained in the early empirical
attempts, rapidly lead to a widespread use of SCIT, which
remained for decades the only form of allergen immuno-
therapy. Some clinicians occasionally attempted to use
routes different from the subcutaneous one [159–161],
but the alternatives to SCIT remained of very limited
interest for many years [162].
SIT is started by increasing subcutaneous injections of
allergen up to a maintenance dose. Several protocols of
SCIT administration (mainly regarding the modality to
achieve the maintenance dose) have subsequently been
proposed and used in clinical practice, such as the “rush”,
ultra-rush or the “cluster” [163, 164].
After reaching the maintenance dose, the interval be-
tween injections is usually increased to monthly, and
continued for 3 to 5 years. For hymenoptera venom al-
lergy, the interval between maintenance doses can be de-
layed to every 4 months [165], and performed life-long
especially in patients with significant risk factors such as
mastocytosis or previous severe sting reactions.
Indications to SCIT
Allergen-specific immunotherapy (SIT) is a “biological
response modifier” that affects the immune response to-
wards allergens at different levels. For this reason, SIT is
currently considered a cornerstone of the management
of allergic respiratory diseases (allergic rhinitis/asthma)
and of Hymenoptera venom allergy.
Age limitation
Usually SCIT is considered in children 5 years and older.
Description of adverse/unintended reactions associated
with SCIT
1. Type and spectrum of adverse events (AEs)
After the earliest descriptions of AEs due to SCIT
[165] these are generally classified according to a
system introduced in Europe since the 1990s [166]
(largely based on the Mueller’s classification for
hymenoptera venom reactions) [167] and up-dated
by the World Allergy Organization and other
organizations [168, 169]. Nonetheless, other classifi-
cations have been repeatedly proposed (for review
see 174), always distinguishing between local and sys-
temic reactions, grading systemic reactions according
to their severity and the number of organs involved,
and distinguishing between early (<30 min) and delayed
reactions [162, 163, 168, 170]. Local reactions are
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limited to the site of injection and include itching,
swelling, pain or induration.
Systemic reactions include rhinoconjunctivitis,
bronchospasm, urticaria/angioedema, generalized
itching, abdominal cramps sometimes ending as
respiratory failure or shock. Other reactions are
considered nonspecific (headache, tiredness, general
malaise). Also vaso-vagal reactions due to the
injection (nausea, vomiting, bradycardia,
hypotension, sweating) may occur. This again
proposes the distinction between “generic” systemic
adverse events and overt anaphylaxis [171], since the
definition of anaphylaxis itself has been repeatedly
changed during the last years. In general the
involvement of more than one organ/system strongly
suggests anaphylaxis, as well as a clinically relevant
drop in blood pressure, loss of consciousness or
respiratory compromise [171, 172]. The more recent
classification of systemic AEs, has been proposed by
the World Allergy Organization [172]. The majority
of the AEs are immediate (i.e. within 30 min) and
therefore are presumed to be due to specific IgE, but
delayed reactions may also occur.
2. Prevalence of adverse reactions and risk associated
with procedure
The fact that the injection of allergens in atopic
subjects could cause AEs including severe reactions
and even death, had been recognized and published
since the early 1980s [173–175]. The rate of
systemic reactions with SCIT largely depends on the
administration schedule, the type of allergen and the
survey method (e.g. controlled trial VS
questionnaire-based surveys). When evaluating the
data from literature, it has to be noticed that the
practice of SCIT largely differs between USA and
Europe. In USA, allergen mixtures are commonly
used, and the extracts are at higher concentrations
[176], whereas in Europe, the usual attitude is to
vaccinate with few (1 to 3) allergens. On the other
hand, the improved manufacturing procedures and
quality of extracts, the improved standardization of
allergen extracts, and the divulgation/education ef-
forts [163, 164, 168], have probably contributed to
the decline of severe/fatal reactions.
The majority of data on the safety of SCIT come
from the USA surveys that have been regularly
conducted over the past 40 years. According to past
and more recent surveys the occurrence of fatal
adverse events is less than 1 per 2,500,000 injections
[177–181], although the occurrence of fatal or near
fatal events has progressively declined over the years
[179, 182–184]. The occurrence of systemic AEs
with SCIT is approximately 0.05–0.6 % of doses
administered. On the other hand, no large
population-based surveys have been conducted
among the European Countries, and the data from
clinical trials are largely incomplete [185]. To date,
the largest safety survey on SCIT was conducted in
Italy [186], which analyzed over 1,700 patients, show-
ing a 3.3 % of systemic reaction rate with no fatalities.
3. Risk factors for adverse reactions
Based on the available data derived from the large USA
surveys as well as European data reports, severe and
uncontrolled asthma seems to represent the most
prominent risk factor for severe side effects [177–179].
Other factors indicated in the official position papers
have to be considered as relative contraindications and
should be considered individually [168]. This is
especially true for children below the age of 5, where
severe AEs are more difficult to recognize and to treat
[168]. Another well recognized risk factor is human
error, including wrong dosing administration, injection
into vessels, and lack of emergency measures
immediately available [187]. Although in the past it was
reported that large local reactions are more frequently
described in those patients who experience systemic
reactions, it is now well accepted that on an individual
basis large local reactions are poor predictors of future
systemic reactions [188].
Finally, it has been sometimes suggested that SIT can
induce autoimmune diseases. Recently published data,
however, demonstrate no increase in autoimmune
disease, and thus recommendations state that it
should not be considered a contraindication to the
treatment [189]. Recent data have also shown no need
to avoid its use in well controlled HIV infection [190,
191]. Pregnancy seems not to be a significant risk
factor for SIT [191, 192]. Although a hypothetical risk
can exist, based on pathophysiologic considerations,
there is no evidence that the use of betablockers
(especially the cardioselective ones) or angiotensin
inhibitors enhance the risk of adverse events in
patients taking SCIT [193, 194].
Institutional/organizational safety recommendations
EAACI, Immunotherapy Task Force. Standards for practical
allergen-specific immunotherapy (2006 Alvarez-Cuesta E)
[163]
Allergen immunotherapy: a practice parameter third
update (2011 Cox L et al) [164]
Sublingual immunotherapy: World Allergy Organization
position paper 2013 update [195]
WAO safety recommendations for SCIT
These WAO recommendations refer to subcutaneous
form immunotherapy (SCIT) only. Sublingual immuno-
therapy (SLIT) has not been included in this document
since the vaccine (drops or tablets) is NOT administered
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in a medically supervised setting. Although the first dose
of allergen vaccine may be administered at the allergist’s
office, it has never been a formal requirement.
1. Site:
SCIT treatment may be started and continued in an
outpatient setting
2. Personnel:
Only trained allergist may initiate and supervise
SCIT. The injections can be made by a nurse under
physician supervision.
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
Should be available on site (in less than 5 min) or
within 30 min, depending on the risk assessment
5. Pretreatment:
The use of premedication with oral
antihistamines/oral antileukotrienes still remains a
matter of debate. On one hand it has been
claimed that premedication may delay or mask
systemic reactions. On the other hand, it has been
reported that premedication could reduce the
frequency and severity of AEs. The strength of
recommendation on this matter is still weak, thus
its employment largely remains in the hands of
the physician.
6. Precautions and duration of the supervised follow up
after procedure:
Although some of the adverse events of SCIT can be
avoided, others occur unpredictably and without
explanation. Immunotherapy should be administered
with a 26- to 27-gauge syringe, and the injection
should be given subcutaneously in the lateral/posterior
portion of the arm. The skin should be pinched and
lifted off of the muscles to avoid intramuscular or
intravenous injection and the skin should be wiped
with disinfectant before giving the injection.
It is well known that some fundamental precautions
can be taken to reduce the risk of severe/fatal AEs.
First, the correct administration (i.e., patient’s name,
batch, and allergen) has to be verified and recorded.
As recommended in all guidelines it is essential that
the patient have a careful examination and medical
history taken [168–172, 174–187]. These include the
objective assessment of current respiratory
symptoms/signs (e.g. asthma/rhinitis), the evaluation
of previous systemic reactions to SCIT (immediate
or delayed), and the presence of any concomitant
acute respiratory illness. When feasible, a Peak
Expiratory Flow evaluation should be done,
considering a value of less than 70 % of best predicted
a warning signal [162, 163, 167]. After each injection
the patient should be observed for at least 30 min.
7. Contraindications:
Pregnancy has been always prudently suggested as a
potential contraindication to SIT, and to SCIT in
general, although no evidence was present in the
literature. A recent survey demonstrated that the
use of SIT in pregnancy, when clearly indicated,
does not increase the risk of perinatal or foetal
adverse events [191, 192]. The suggestion of not
starting SCIT during pregnancy, and not stopping
an already ongoing SIT remains valid, based on
common sense.
8. Other safety considerations:
Safety of maintenance of SCIT may be improved by
monitoring of symptoms, appropriate adjustment of
vaccine dosing etc.
Venom immunotherapy
Definition and technical description of the procedure (VIT)
Venom immunotherapy (VIT) is so far the only ef-
fective treatment that prevents anaphylaxis and im-
proves quality of life in patients with venom allergy
[23, 196–198]. Several protocols of VIT have been de-
scribed and used in clinical practice: Conventional
protocols are started with weekly injections of in-
creasing venom doses from 0.01 to 100 μg over
2 months. In rush protocols the increase to the main-
tenance dose is reached by daily increasing doses of
venom for 2 to 3 days. In ultrarush protocols the in-
crease to a total dose of 100 μg is reached by injec-
tions every 30 min in 3.5 h (Table 1) [196]. After
reaching maintenance dose the interval of injections
is increased from weekly to monthly, and 6–8 weeks
from the second year. The recommended duration of
VIT is 3 to 5 years, in patients with risk factors like
mastocytosis or previous severe sting reactions, VIT
may be continued indefinitely or as long as the risk
of accidental stings remains. The maintenance dose of
100 μg protects over 95 % of wasp and ant venom al-
lergic and 80–90 % of bee venom allergic patients
from systemic allergic reaction (SAR) when re-stung
[148, 196, 197]. In case of a SAR to a re-sting during
VIT an increase of the maintenance dose to 200 μg
protects most of these patients from further SAR
[196].
Indications for VIT
US guidelines recommend VIT in all patients with a his-
tory of SAR and positive diagnostic tests – skin tests
and/or venom specific serum IgE. Excepted are children
with only cutaneous reactions [23]. European guidelines
[196] do not recommend VIT also in adults with only
cutaneous reactions, unless there are special risk factors
or a severe reduction of QOL [198].
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Age limitation
VIT may be given to children including those of pre-school
age [23, 196], although the balance between discomforts
versus benefits of treatment should be considered on an in-
dividual basis. In general, it is best to wait until a child is
old enough to understand and accept the treatment. Elderly
patients have an increased risk of very severe SAR to acci-
dental stings with lasting morbidity, e.g. myocardial infarc-
tion, cerebral infarction or even fatal outcome [199, 200],
which may be prevented by VIT. Although older age and
comorbidities also increase the risk of reactions to VIT it-
self, these are usually milder and easier to manage than a
field sting. Therefore, there is no upper age limit for VIT.
Adverse reactions associated with VIT
1. Type and spectrum of adverse reactions
Local reactions at the injection site are common,
and may be large (>5 cm in diameter) or last more
than 24 h. Immediate-type adverse reactions are
common during VIT. The majority of these are mild
skin-only reactions, but some may be severe.
2. Prevalence of adverse reactions and risk associated
with procedure
The reported proportions of patients experiencing one or
more significant reactions requiring medical intervention
are 10–20 % for bee andMyrmecia ant VIT, and 5 % for
VespulaVIT [23, 148]. Fatal reactions to VIT have not
been reported. Rush and ultrarush protocols (Table 1)
protect most patients more rapidly but may increase the
number of SAR side effects [196, 201].
3. Risk factors for adverse reactions
In addition to the species of venom used, risk factors
for SAR due to VIT include older age, coexisting
cardiovascular or pulmonary disease,
antihypertensive medications, elevated baseline
serum tryptase and mastocytosis [200–204].
Intercurrent illnesses (e.g. fever, infection) may also
increase the risk of an adverse reaction. Dialysed
aqueous venom and Aluminium hydroxide depot
extracts have somewhat lower risks of SAR [205, 206].
Institutional/organizational safety recommendations
The most recent international guidelines addressing
the issue of VIT safety are: The guidelines of the
EAACI [195]. The practice parameter update 2011 of
the AAAAI [23] and the WAO anaphylaxis guidelines
2013 [207].
WAO safety recommendations
1. Site:
 Both hospital and outpatient clinic settings
 VIT treatment may be started and continued
either at a hospital or in the office
2. Personnel: technician/nurse/physician
The treating physician should recommend and
supervise VIT. The injections can be made by a
nurse under physician supervision.
3. Emergency equipment availability
Should be available on site (mandatory)
4. Emergency staff (ICU) availability
Should be available on site (in less than 5 min) or
within 30 min, depending on the risk assessment
and the immunotherapy protocol used.
5. Pretreatment
Pre-treatment with oral antihistamines during the
dose build-up phase reduces the risk of SAR during
VIT, and does not impact on the overall efficacy of
VIT [208].
6. Precautions and duration of the supervised follow up
after procedure
 xPrior to each VIT injection, the patient should
be asked about: (i) reactions or unexpected
symptoms following the last visit or injection,
and; (ii) any new health problems including newly
prescribed medications. Blood pressure and pulse
rate should be routinely measured before every
injection is given. Issues identified may lead to
modifications as follows:
– Reactions on previous visits or injections
consider reduced VIT dose
– Intercurrent illness consider delaying
treatment
– Newly prescribed antihypertensive medications
consider temporarily withholding
antihypertensive medications for 24–48 h
prior to each visit for VIT.
– Poorly controlled blood pressure or new onset
(or worsening) of possible cardiac or lung
disease (e.g. angina, asthma) consider pausing
VIT until further investigations and/or
stabilisation of condition.
 After each injection the patient should be
observed for at least 30 min.
 If there is no SAR the next injection can be given
or the patient can be discharged after 30 min of
observation.
7. Contraindications
Contraindications for VIT are concomitant active
neoplastic and auto-immune diseases [194]. VIT
should not be started during pregnancy but can be
continued if well tolerated before pregnancy.
8. Other safety considerations
 Safety of maintenance VIT may be improved by
careful monitoring of symptoms and appropriate
adjustment of vaccine dosing.
 After an SAR the next injection dose should be
decreased.
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 Discharge may be considered 1 h after complete
regression of all symptoms, but after a severe
reaction (hypotension or hypoxemia), observation
for a longer period should be considered.
 If there are repeated SAR due to VIT, pre-treatment
with oral antihistamines on the evening before and
1 h before the following VIT injections should be
considered [208].
 Other options are to switch to a conventional
protocol using dialysed aqueous or Aluminium
hydroxide depot preparations [205, 206], and
pretreatment with Omalizumab [209].
Oral Immunotherapy for Food Allergy (OIT)
Definition and short technical description
Oral immunotherapy is a promising concept for the
treatment of food allergy. The majority of clinical trials
focused on peanut, cow’s milk, and hen’s egg allergy
[210, 211]. Meta-analysis revealed a substantially lower
risk of reactions to the relevant food allergen in those
receiving OIT [211]. There are several protocols for OIT
used throughout the world [212]. In general, OIT starts
with oral administration of very low doses of food pro-
tein, e.g. 2 mg of peanut protein [213], which is given on
a daily basis. The doses are progressively increased over
time. Regular dose increments, e.g. biweekly, are per-
formed mostly under medical supervision [212]. When a
defined target dose is reached, this maintenance dose,
e.g. 800 mg peanut protein [213] is continuously admin-
istered on a daily basis and continued for several years.
However, it is important to note that, in fact, mainten-
ance dose ranged among various centers from 400 to
8000 mg of peanut protein [214]. Moreover, to date
there is no recommended duration for OIT as long-term
studies are still missing [211].
Clinical indications
OIT is a promising treatment approach, but it is associ-
ated with risk of adverse reactions, including anaphyl-
axis; it is therefore not currently recommended for
routine clinical use [215]. Patients with peanut or tree
nut allergy might especially benefit from OIT, as natural
tolerance is rare. In addition, patients with persistent
cow’s milk or hen’s egg allergy will be candidates. The
objective of OIT is to achieve first a clinical desensitization,
which means the tolerance to a certain amount of the
allergen with an ongoing therapy, and later a long-term
tolerance, which means the permanent loss of reactivity
also after stopping OIT [212].
Age limitations
OIT could be performed at all ages; however, most OIT
trials have been performed in children [210, 211].
Description of adverse reactions associated with the
procedure
1. Type and spectrum of adverse reactions
The most common adverse reactions are local, e.g.,
oral pruritus, or gastrointestinal, e.g., abdominal
pain. More severe adverse reactions affect the
respiratory tract, e.g., wheezing or multisystem
reactions
[210–212]. The development of allergic eosinophilic
esophagitis has been described [216].
2. Prevalence of adverse reactions and risk associated
with the procedure.
Currently OIT is only recommended in controlled
clinical studies until the short- and long-term safety
profile is better known and understood [215].
3. Risk factor for adverse reactions
Augmentation factors, e.g., infection, menses and
exercise seem to be risk factors for adverse
reactions.
Institutional / organizational safety recommendations
EAACI food allergy and anaphylaxis guidelines: diagno-
sis and management of food allergy [215].
WAO safety recommendations
1. Site:
 Both hospital and outpatient clinic settings;
however, OIT is currently not recommended for
routine clinical use [214, 215].
2. Personnel: technician / nurse / physicians:
 Physicians experienced with food allergy and
specific immunotherapy should recommend and
supervise OIT. During the build-up phase food
should be administered by a nurse under
physician’s supervision.
3. Emergency equipment availability:
 Should be available on site (mandatory)
4. Emergency staff (ICU) availability:
 Should be available on site (in less than 5 min) or
within 30 min, depending on the risk assessment.
5. Pretreatment:
 Antihistamines or omalizumab can be considered
6. Precautions and duration of the supervised follow-up
after procedure:
 During the build-up phase, doses are progressively
increased over time, e.g. biweekly, under medical
supervision [212, 213]. After each dose the patient
should be observed for at least 2 h. The same dose
is given at home daily until the next increase. In
the maintenance phase the tolerated dose is given
daily at home [212, 213].
7. Contraindications:
 Commonly, OIT is not performed in patients
with unstable asthma or in pregnancy.
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8. Other safety considerations:
 Doses should be adjusted during infection as this
has been described as an important augmentation
factor.
Drug desensitization
Definition and short technical description
The term desensitization is used for procedures inducing
clinical tolerance or tolerization to drugs eliciting hyper-
sensitivity reactions [217, 218]. Rapid desensitization
protocols are used for type I IgE/mast cell-mediated al-
lergic reactions and slow desensitization protocols are
used for type IV delayed drug hypersensitivity reactions
[218] and other hypersensitivity reactions such as aspirin
exacerbated respiratory disease (AERD) [138].
Desensitization procedures are based on protocols in
which suboptimal doses of the drug allergens are re-
introduced, starting at 1/100 to 1/1000 the target dose
or lower for patients presenting severe reactions, and in-
creasing at fixed time intervals by doubling or higher in-
crements until reaching the target dose. These protocols
introduce the sensitizing medication in few hours up to
6–8 h. Desensitization protocols allow allergic patients
to receive their first line therapeutic agents to treat in-
fections, cancer or chronic inflammatory diseases. The
induction of clinical tolerance is temporary and largely
depends on the half-life of the medication. The
desensitization state persists from few hours, in the case
of antibiotics administered every 6 to 8 h to several days
in the case of aspirin. It is generally accepted that once
more than two half-lives of the medication have spanned
the patient is no longer desensitized and will need re-
desensitization. Successful desensitization can be
achieved in patients with IgE/mast cell mediated hyper-
sensitivity reactions (allergy to beta lactams or other an-
tibiotics) [219] and platinium salts [220, 221] who
present symptoms including urticaria, angioedema,
wheezing, laryngeal edema, nausea, vomiting, diarrhea
or hypotension. Anaphylaxis in which tryptase levels are
found elevated in serum is not a contraindication for
rapid desensitization. Other hypersensitivity reactions
(patients with aspirin exacerbated respiratory disease
[222], non-beta lactam antibiotics [223], sulfonamides
[224] and other chemotherapeutics including mono-
clonal antibodies [221]) have been successfully desensi-
tized with different and slow protocols, some of them
involving several days. Patients with chronic urticaria
exacerbated by aspirin and other NSAIDs (named
NSAIDs Exacerbated Cutaneous Disease-NECD) may
be refractory to desensitizations [225] with few suc-
cessful cases [226]. There are few standardized proto-
cols for delayed reactions and caution has to be taken
to avoid desensitization in patients with severe cutane-
ous or systemic reactions. Only patients with non-
severe delayed reactions are candidates for slow desen-
sitizations [218].
Clinical indications for drug desensitization
Rapid and slow drug desensitizations are indicated:
1. If the drug is considered first line therapy (e.g.
patients with platin-sensitive recurrent ovarian
cancer, cystic fibrosis patients with antibiotics
allergy, patients with NSAIDS intolerance in need of
dual antiplatelet therapy).
2. If the drug is more effective than the alternatives.
3. If non-cross reacting therapeutic agents are
unavailable.
4. The drug administrated after desensitization has a
unique therapeutic effect (aspirin in patients with
NSAIDs – exacerbated respiratory disease
complicated with nasal polyps).
Age limitation
Most published protocols assess clinical efficacy of
desensitization in adult populations. There are several
published desensitization protocols for children
(desensitization protocols to antibiotics [227] and
chemotherapy [228]). The success rate of adult and
pediatric desensitization protocols is similar with a
range from 50 to 100 %.
Adverse/unintended reactions associated with the drug
desensitization
In 30 to 50 % of all desensitization procedures mild symp-
toms occur and there are no reported deaths resulting
from a desensitization protocol. Anti-histamines are used
commonly as pre-medications and some protocols are
modified once patients have presented reactions to subse-
quent desensitizations [228].
1. Type and spectrum of adverse reactions
Most of the desensitization protocols are well
tolerated by the majority of patients. However,
reintroduction of a drug to an allergic patient carries
high risk including anaphylaxis.
Reactions during rapid desensitization protocols can
occur in minutes and can range from flushing and
urticaria to hypotension and oxygen desaturation.
During aspirin desensitization in patients with
Aspirin Exacerbated Respiratory Disease (AERD) the
tolerant state is achieved by repeating the provoking
dose of aspirin so that aspirin sensitivity has to be
demonstrated during the procedure. Thus, except
for so called “silent desensitization” adverse reaction
(respiratory or cutaneous) are intentionally evoked
during the procedure, but the magnitude is
controlled and limited by rapid administration of
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reliever drugs. These reactions can appear at every
step of desensitization protocols. In patients
desensitized to aspirin, breakthrough reactions
usually occur after the oral dose of 45–60 mg of
aspirin [229] but it can be seen at higher doses.
Protocols for rapid desensitization to aspirin in
patients with cutaneous symptoms differ from the
AERD protocols [225, 230] in which the prevalence
of adverse reactions is only up to 19 %.
During intravenous rapid desensitization protocols
most of the adverse reactions are seen when the
drug is infused at the maximal concentration and
during the last step of the protocol [221].
2. Prevalence and risk associated with the procedure:
Side effects may complicate 12 to 52 % of
desensitizations to antibiotics and from 4–33 % of
desensitizations to chemotherapeutics and 29 %
desensitizations to monoclonal antibodies [220, 221].
In repeated desensitizations the rate of adverse
reactions decreases to less than 10 % with over 6–10
desensitizations [221] and the spectrum of reactions
ranges from cutaneous reactions [228] to
anaphylactic shock [220].
3. Risk factors for adverse/unintended reactions
The severity of the initial hypersensitivity reaction is
the most important risk factor, but other factors
such as the time course of the HS reaction (in patients
with delayed HSR it is most reasonable to hospitalize
patients for longer time), the concomitant use of other
medications such as beta-blockers and ACE inhibitors
and the severity of the underlying disease need to be
taken into consideration.
For patients desensitized to chemotherapy and
monoclonal antibodies the presence of atopy, a
previous severe reaction and the presence of severe
cardiovascular disease are risk factor for severe
reactions. In addition patients on beta blockers and
on ACE inhibitors are at risk for severe hypotension
and cardiovascular collapse during desensitization.
Risk factors for severe or moderate reaction during
aspirin desensitization include: age: 30–40, duration
of AERD less 10 years, FEV1 < 80 %, uncontrolled
asthma, previous asthma –related ED visits and lack
of antileukotriene pretreatment [229].
Institutional/organizational safety recommendations
Not available
WAO safety recommendations
1. Site:
 Both hospital and outpatient clinic settings
 Comment:
– All high risk desensitizations should be done
in the intensive care unit. High risk
desensitizations are those performed on
patients with initial grade 3 anaphylactic
reactions associated with hypotension and/or
oxygen desaturation, patients with severe/
unstable cardiovascular diseases and/or on
beta blockers and patients with FEV1 < 70 %.
– Once high risk patients have presented a
successful desensitization in the intensive care
unit repeated desensitizations can be done in
the outpatient setting provided resuscitation
medications including epinephrine, oxygen and
intubation materials are available.
– Patients with hypersensitivity reactions
involving the skin and/or two organs without
changes in vital signs can be desensitized for
the first time in the outpatient setting with
trained staff and emergency equipment
available on site (see below).
– In patients requiring repeated desensitizations
(desensitizations to chemotherapy, monoclonal
antibodies), after an initial successful
desensitization, subsequent procedures can be
performed in outpatient settings.
– For patients with delayed drug hypersensitivity
slow desensitization protocols can also be
done as outpatient procedures based on the
severity of the initial reaction and the disease
being treated (allopurinol desensitization for gout)
2. Personnel:
Desensitization should be supervised by
well-trained, experienced allergists and nurses. One
on one nursing should be available for each
desensitized patient and an allergist should be
available on site at less than 3 min of the
desensitization procedure.
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff availability
Should be available on the site
5. Pretreatment
Pretreatment with systemic steroids is not
recommended unless required by current guidelines
for cancer treatment (dexamethasone for taxanes
administration) [231]. Pretreatment with H1 and H2
antihistamines is recommended for rapid
desensitization for chemotherapy, monoclonals and
antibiotics but no controlled studies have been done
comparing outcomes of desensitizations with and
without pre-medications [221, 232]. Whitaker et al.
[233] indicated that pretreatment with antihistamines
alone or with glucocorticosteroids did not reduce the
risk of reactions in desensitized patients. Leukotriene
receptor blockade with montelukast and prostaglandin
inhibition with aspirin have provided excellent
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protection against severe reactions in patients
desensitized to chemotherapy and monoclonals
[234, 235]. In early trials with paclitaxel and docetaxel
approximately 30 % of patients presented acute
infusion reaction and pretreatment with antihistamines
and glucocorticosteroids and slower infusion rate
reduced the rate of adverse reactions to 10 % [236].
Based on these results many current chemotherapy
regimens include pretreatment with corticosteroids,
antihistamines and proton-pump inhibitors.
Although some authors [217] do not recommend
pretreatment with antihistamines as it may mask
early signs of hypersensitivity reaction [138], current
studies in populations of desensitized patients without
pre-medications are lacking and no recommendations
can be made.
Leukotriene receptor antagonists may alleviate
symptoms of breakthrough reactions in aspirin
hypersensitive patients [237] by shifting reaction
from bronchial to naso-ocular symptoms and these
pre-medications are strongly recommended at the
present time for all patients desensitized to aspirin.
6. Precautions and duration of the supervised follow up
after procedure
The severity of the initial hypersensitivity reaction is
the most important risk factor, but other factors such
as the time course of the HS reaction (in patients with
delayed HSR it is most reasonable to hospitalize
patients for longer time), the concomitant use of
other medications such as beta-blockers and ACE
inhibitors and the severity of the underlying disease
need to be taken into consideration.
Patients should be in stable condition (FEV1 > 70 %
in patients with asthma) before the start of the
desensitization. In patients with cystic fibrosis the
baseline FEV1 may be substantially lower and risk
assessment should be done but low FEV1 is not
considered a formal contraindication for
desensitization.
Duration of the supervision depends on the initial
hypersensitivity reactions. In case of immediate
reactions, rapid desensitized patients to
chemotherapy, monoclonal and antibiotics are
supervised for 30 min in the hospital for acute post
desensitization reactions and then for the next
24–48 h for delayed post desensitization reactions.
7. Contra-indications
The contra-indications to drug desensitization may
be absolute or relative, when the risk /benefit
evaluation is performed.
 Absolute contraindications
– Previous severe/life threatening cutaneous
drug induced disease (SJS/TEN, DHS/DIHS/
DRESS, AGEP)
– Cutaneous and systemic vasculitis
– Drug induced autoimmune disorders
– Drug induced organ involvement (hepatitis,
nephritis, cytopenias, pneumonitis)
– Immune complex disorders (serum sickness
disease)
 Relative contraindications
– Treatment with beta blockers and ACE
inhibitors
– Unstable underlying disease (asthma, coronary
heart disease)
Maculo-papular rashes are not contraindications for
desensitization and slow protocols are generally
successful.
8. Other considerations:
Treatment of chronic disease should be continued,
but drugs that can influence the course of reaction
like beta blockers and ACE inhibitors should be
discontinued at least 24 h prior to desensitization to
avoid prolonged and intractable hypotension during
anaphylaxis induced by the desensitization procedure.
Treatment with Anti-IgE and other biologicals
Definition and short technical description
Omalizumab is a humanized monoclonal antibody di-
rected against human IgE. It prevents binding of soluble
IgE to the IgE receptor. This is currently the only mono-
clonal antibody directed against IgE which is licensed.
Indication
Omalizumab is indicated for adults and adolescent and
children (6 years of age and above) with moderate to se-
vere persistent asthma, who have a positive skin test or
in-vitro reactivity to a perennial aeroallergen and whose
symptoms are inadequately controlled with inhaled cor-
ticosteroids [238–244]. Although new clinical data sug-
gest that there are also other patient populations with
asthma or other allergy or atopy related conditions, who
would benefit from with Omalizumab, the clinical indi-
cation is currently limited to the above described patient
group. More recently omalizumab has been approved
for use in chronic idiopathic urticaria [245].
Age limitations
Anti-IgE is indicated for adults and adolescence (12 years
of age and above).
Description of adverse reactions
1. Anaphylaxis
The frequency of anaphylaxis attributed to Omalizumab
is estimated to be at least 0.2 % of patients, based on an
estimated exposure of about 57,300 patients from June
2003 through December 2006. Anaphylaxis has occurred
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as early as after the first dose of Omalizumab, but also oc-
curs beyond 1 year after beginning of regularly scheduled
treatment [246]. Omalizumab has received a box warning
label by the FDA [247–249].
2. Malignancy
Although malignant neoplasms were observed in 20 of
4,127 (0.5 %) Omalizumab-treated patients compared to
5 of 2,236 (0.2 %) control patients in clinical studies, the
direct relationship between this treatment and the devel-
opment of malignancies is completely unclear. The
observed malignancies in Omalizumab-treated patients
included a variety of different types, including breast,
non-melanoma skin, prostate, melanoma, and others
[238]. However, the impact of longer exposure to
Omalizumab, or the use in patients at higher risk for
malignancies, is not known and the application of
omalizumab in patients with preexisting malignancies
contradicted [239].
3. Eosinophilic conditions
In rare cases, patients with asthma on therapy with
Omalizumab presented a serious systemic eosinophilia,
sometimes presenting with clinical features of vasculitis,
consistent with Churg-Strauss syndrome.
4. Fever, arthralgia, rush
Some patients have experienced a constellation of
signs and symptoms including arthritis, arthralgia, rush,
fever and lymphadenopathy with an onset 1 to 5 days
after the first of subsequent injections.
5. Parasitic infection
It is not clear if treatment with omalizumab may be
associated with increased morbidity attributable to para-
sitic infections [240].
6. Immunogenicity
Omalizumab does not seem to be associated with de-
velopment of immunogenicity [243].
Institutional/organizational safety recommendations
Not available
WAO safety recommendations
1. Setting:
Both hospital and outpatient clinic setting
2. Personnel:
All personnel, supervising the patient during and after
the injection, should be trained to handle anaphylactic
reactions.
3. Emergency equipment availability
Should be available on site (mandatory)
4. Emergency staff availability
Should be available on site (in less than 5 min)
5. Pretreatment
No pretreatment
6. Precautions and duration of the supervised follow up
after procedure
Following immediate reaction and intervention in the
rare case that anaphylaxis occurs, the patient should be
further followed up in an appropriate emergency setting.
Consider in-office waiting time – 2 h for the first injec-
tion of omalizumab and then 30 min after each subsequent
dose. Patient should have an epinephrine autoinjector
available [250].
7. Contraindications
The use of Omalizumab is contraindicated in the
patients with a history of severe hypersensitivity reac-
tions to Omalizumab or any of the preparation’s
ingredients. Furthermore Omalizumab should not be
used to treat acute bronchospasm or status
asthmaticus.
Treatment with products from human plasma
Definition and short technical description
Products made from human plasma are increasingly being
used also in the field of allergy and asthma treatment.
They include preparations of human immunoglobulins
[251, 252], used for subcutaneous and intravenous admin-
istration. More recently, also other plasma components
have been isolated and made available in commercial
preparations, which can be used for various other
conditions. A prominent example is the C1 esterase
inhibitor [253]. C1 esterase inhibitor is manufactured
from human plasma, purified by a combination of fil-
tration and chromatographic procedures. Several pre-
cautions have been implemented to reduce the risk of
viral transmission, since this factor, as well as
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immunoglobulin preparations in general, are being de-
rived from a large pool of donors.
Indication
Indications for the use of human immunoglobulin prepa-
rations are the treatment of primary humoral immuno-
deficiencies, chronic immune thrombocytopenic purpura,
and others [251, 252, 254, 255].
C1 esterase inhibitor is indicated for routine prophylaxis
against angioedema attacks in patients with Hereditary
Angioedema (HAE) [254].
Age limitations
Immunoglobulins are available for all ages, but some C1
inhibitor preparations have limited recommendations in
children.
Description of adverse reactions
All adverse reactions are related to direct or indirect ef-
fects and mechanisms, known to occur by human im-
munoglobulins and plasma preparations [256]. These are
particularly:
 Hypersensitivity reactions
 Renal dysfunction and renal failure
 Thrombotic events
 Hyperproteinemia, increased serum viscosity, and
hyponatraemia
 Aseptic meningitis syndrome (AMS)
 Hemolysis
 Transfusion related acute lung injury
 Volume overload
 Transmissible infectious agents
 Interference with laboratory tests, due to the
passively transferred antibodies in immunoglobulin
preparations
The following risk factors have been identified for the
development of thrombosis:
 Advanced age, prolonged immobilization,
hypercoagulable conditions, history of venous or arterial
thrombosis, use of estrogens, indwelling vascular
catheters, hyperviscosity and cardiovascular risk factors.
 Patients predisposed to renal dysfunction, including
those with any degree of pre-existing renal
insufficiency, diabetes mellitus, age > 65, volume
depletion, sepsis, paraproteinaemia, or patients
receiving no nephrotoxic drugs.
 The only serious adverse reaction observed in
clinical studies with C1 esterase inhibitor was
cerebrovascular accident. The most common
adverse reactions observed have been headache,
nausea, rash and vomiting.
Institutional safety recommendations
Not available.
WAO safety recommendations
1. Site:
Both hospital and outpatients clinic settings
2. Personnel:
All personnel in direct contact to the patient must
be experienced in handling hypersensitivity
reactions.
3. Emergency equipment availability:
Should be available on site (mandatory)
4. Emergency staff availability:
Should be available on site (in less than 5 min)
5. Pretreatment:
Pretreatment regimen including analgesics,
antihistamines, and/or anti-inflammatory medications,
steroids, hydration may be indicated in some patients
to avoid or diminish common adverse effects
6. Precautions during the supervised follow up after
procedure:
Based on the individual risk of the patient (see
above), special precautions have to be taken before
administering these preparations. They may include,
but are not limited to: Periodic monitoring of renal
function and urine output, assessment of blood
viscosity, analysis of signs and symptoms of
hemolysis, and the presence of anti-neutrophil anti-
bodies and anti-HLA antibodies in both, the product
and patient serum. These should be obtained in case
of an increased index of suspicion.
7. Contraindications:
Immunoglobulin preparations are contraindicated in
patients who have a history of anaphylactic or severe
systemic hypersensitivity reactions to the administration
of human immunoglobulin. Administration is also
contraindicated in IgA-deficient patients with
antibodies to IgA and a history of hypersensitivity.
Anaphylaxis has been reported with the intravenous
use of immunoglobulin preparations and is theoretic-
ally possible following subcutaneous administration.
The C1 esterase inhibitor is contraindicated in
patients who have manifested life-threatening
immediate hypersensitivity reactions, including
anaphylaxis to the product.
8. Other considerations:
In case of hypersensitivity reactions stop infusion of
injection immediately. Have epinephrine
immediately available for treatment.
Management of emergencies in allergy practice
All medical staff involved in either diagnostic or therapeutic
allergy procedures should be trained in the recognition and
management of allergic emergencies including anaphylaxis.
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Recommended equipment and medications
The following equipment is necessary at the allergy
office performing diagnostic allergy procedures:
Equipment
1. Trolley for patient to lie flat if needed
2. Oxygen and suction equipment, including tubing,
masks etc.
3. Airway management equipment according to skill
level (basic essentials are oral and nasopharyngeal
airways, bag-valve-mask for ventilation)
4. Intravenous access cannulae (20-16G) and giving
sets; needles and syringes.
5. Manual blood pressure cuff
6. Nebulizer mask (for inhaled/nebulized
epinephrine)
Note: In a hospital setting it is recommended that
there also be immediate access to ECG, pulse
oximetry and non-invasive blood pressure monitoring
equipment, advanced airway management devices for
intubation and cricothyrotomy, and an intravenous
infusion pump.
Drugs and fluids
1. Epinephrine (2 packs of 5 ampoules of 1 mg/1 ml)
2. Corticosteroid for intravenous injection
3. Antihistamines for oral or intravenous use
4. Two 1 L bags of normal saline
Note: In a hospital setting, it is recommended
that there also be immediate access to (a) smaller
bags of saline for setting up an epinephrine
infusion according to local hospital protocol and
(b) a second line vasoconstrictor (metaraminol or
vasopressin)
Management of adverse reactions
Algorithms for management of allergic emergencies have
been described by several state- of- the-art documents
available [206, 207, 257–259]. Management of excessive
or emerging adverse reaction should be prompt, but
must be preceded by assessment of the situation and
should involve careful clinical assessment of a patient.
Any intervention should be tailored to the type and se-
verity of symptoms and vital signs.
1. Local/Mild reactions
 Allergy skin testing or allergen injection during
immunotherapy which are associated with
development of local redness, edema and pain
can be relieve by local application of cold
compresses followed by oral antihistamine. For
mild allergy symptoms, such as hay fever or
hives, an oral antihistamine may be sufficient. For
stuffy nose, decongestant can be given and for
itchy, watery eyes, allergy eye drops may be
sufficient.
 Difficulty breathing or wheezing related to e.g.
inhaled allergen or oral food challenge should be
assessed by measurement of respiratory function
(spirometry) and could be relieved by inhalation
of 2 puffs of albuterol or other beta2-agonist from
an MDI
 If other symptoms like swollen lips, tongue,
tightness in the throat, hoarseness or trouble
speaking occur they should be consider as
potential developing laryngeal edema and
injection of adrenaline should be considered.
Similarly, symptoms such as nausea, abdominal
pain, vomiting, tachycardia, anxiety or dizziness
may herald development of anaphylaxis and
should be treated accordingly.
 The patient even with mild symptoms related to
the procedure should be observed continuously
and any worsening of symptoms should be
assessed as potential signs of anaphylaxis.
2. Severe allergic reactions
If criteria for a diagnosis of anaphylaxis are met
(that is, involvement of two or more organ
systems, or the onset of cardiovascular collapse/
hypotension, an appropriate treatment protocol
(Table 4) should be initiated. The reaction
(although rarely) may not respond to a single
intramuscular dose of epinephrine, thus the
supervising doctor should be prepared to escalate
treatment. Reactions limited to the skin may
settle without treatment and/or be managed
symptomatically with oral antihistamines.
Parenteral antihistamines should generally be
avoided as there is no proof of benefit and they
may themselves trigger the onset of hypotension.
The efficacy of steroids is unknown and so their
use is not recommended as a routine.
Summary and recommendations
Diagnosis of allergic disorders may require intentional
exposure of patients to potentially allergenic or irritating
substances and sometimes involves deliberate induction
of allergic symptoms to offending compounds during
provocation tests. Intentional application to a sensitized
patient of potentially dangerous substances (allergy vac-
cines) is also a part of routine management of allergic
diseases. Unwanted, excessive or even dangerous reac-
tions associated with these procedures can be minimized
or even avoided if the procedure is performed in appro-
priate manner and setting, medical personnel are aware
of its potential risk and are prepared to appropriately
handle the situation.
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Following review of available literature the group of
WAO allergy experts, representing various continents
and areas of allergy expertise, reports on risk associated
with diagnostic and therapeutic procedures in allergy
practice. Based on known/expected risk and taking into
account existing allergy guidelines/recommendations a
set of safety requirements for performing allergy proce-
dures have been proposed. The consensus on safety
requirements for performing specific procedures recom-
mends appropriate qualifications of personnel, optimal
setting where the procedure should be performed,
necessary availability of safety equipment, access to
specialized emergency service and required time of
medical supervision. The group proposes also general
recommendations which should be followed in allergy
practice, regardless of the type of diagnostic/therapeutic
procedure.
The general recommendations include:
1. Procedures for the diagnosis and treatment of
allergic diseases should be performed by medical
personnel (physician/nurse/technician) fully aware of
risks associated with the procedure and trained in
the recognition and management of allergic
emergencies, including anaphylaxis.
2. Some procedures can be performed by trained
nurse/technician, but always under close supervision
of the allergist.
3. Although most procedures can be done in both
outpatient and hospital settings availability of
appropriate rescue service should be secured.
4. Basic emergency equipment and rescue medications
should be available on site during each allergy
procedure.
5. Depending on the type of procedure emergency staff
(ICU) should be available on site or should be
reached within a specified time.
6. Before a procedure is initiated, contra-indications
should be considered and risk/benefit ratio for each
procedure should be assessed.
7. The patient should receive full information on the
purpose and potential adverse effects associated with
each procedure and for some procedures should be
asked to sign an informed consent.
8. If anaphylaxis or severe reactions are likely,
intravenous access should be secured before the
procedure is started.
9. Continuous monitoring of patient by authorized
personnel during is the procedure necessary to
secure safety of performed procedure.
10. After the procedure is completed the patient should
remain under close supervision for a specified period
of time.
11. Before the patient is released, she or he should be
provided with appropriate instruction in how to
handle potential adverse symptoms and what to do
in case of an emergency.
12. Medical personnel who have asthma or had a prior
reaction to a testing agent should take precautions to
minimize exposure (adequate ventilation, exhalation
filters, hoods or closed chambers) or avoid performing
these tests.
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Table 4 Standard protocol for anaphylaxis management
1. Initial steps
• Call for assistance
• Give epinephrine 1:1000 at a dose of 0.01 mg/kg IM in the lateral
thigh (maximum 0.5 mg)
• Lie patient flat with legs elevated unless this causes increased
respiratory distress, in which case the patient may prefer to sit up.
However, return to supine position if there is any deterioration in
conscious state
• Airway management (according to skills and equipment) if required
• Document a simple systolic BP by palpation (radial/ brachial pulse)
and then deflate the cuff to just below systolic pressure as a
tourniquet and gain IV access. If equipment is available, start
physiological monitoring (ECG, oxygen saturations, 5 minutely
noninvasive BP) and give oxygen if severe respiratory distress and/or
hypotension.
If the patient is hypotensive, also:
b. Give IV normal saline bolus 20 mL/kg
c. Gain additional wide bore IV access (14G or 16G in adults) and
prepare to give additional fluid and/or adrenaline infusion if the
patient does not respond to initial management
For upper airway obstruction/stridor, also:
d. Continuous nebulization of epinephrine (5 mL of 1mg/ml)
2. If there is inadequate response, an immediate life-threatening situation
or deterioration
• Repeat IM epinephrine injection every 3–5 min as needed or start
an IV epinephrine infusion as per hospital guidelines/protocol.
Monitor BP closely. Nausea, vomiting, shaking, tachycardia or
arrhythmias in the setting of normal or raised BP is likely to
represent adrenaline toxicity rather than worsening anaphylaxis
If the patient remains hypotensive, also:
• Further N/saline fluid boluses (up to 50 mL/kg in total) may be
required in the first 20 min
• In the hospital setting, consider adding a selective vasoconstrictor
(see Table 1).
When indicated at any time, prepare to initiate cardiopulmonary
resuscitation (CPR) including standard IV adrenaline dosing if the patient
goes into cardiac arrest. Prolonged CPR is indicated because the arrest is
usually sudden (no preceding hypoxia) and potentially reversible
3. Disposition
• Consider to use systemic corticosteroids to prevent potential late
phase reaction
Severe reactions should be monitored for a minimum 4 h after the last
dose of adrenaline
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